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Delayed cerebral ischemia (DCI) is a significant complication following aneurysmal 
subarachnoid hemorrhage (aSAH). Recent evidence has suggested that biochemical mediators 
alter cerebral perfusion resulting in neurological decline. Estrogens (estrone–E1 and estradiol–
E2) are mediators with demonstrated neuroprotective properties that could be implicated in DCI. 
The impact of E1 or E2 on outcomes in humans following aSAH has been understudied. The 
purpose of this study was to examine the association between E1 and E2 levels and DCI 
following aSAH. Plasma and cerebral spinal fluid (CSF) samples collected after hemorrhage on 
99 acute, adult aSAH patients admitted to the Neurovascular ICU enrolled in a NIH funded 
study-RO1NR004339.  T hree plasma and up to 5 CSF samples were selected for E1 and E2 
analysis from each patient representing early(1–4), middle(4-6) and late(7-10) days after 
hemorrhage and were assayed using liquid chromatography-tandem mass spectrometry. DCI was 
operationalized as radiographic/ultrasonic evidence of impaired cerebral blood flow 
accompanied by neurological deterioration. Statistical analysis included detailed descriptive, 
group based trajectory and multiple logistic regression using SAS v9.2. 
Group based trajectory identified 2 groups over time for both plasma E1 (61.4% E1-high 
and 38.6% E1-low) and E2 (48% E2-high and 52% E2-low) values using censored normal 
model. Weighted Chi Square analysis identified differences between trajectory groups by 
gender(p=.02), menopause(.05), age(p<.001) and fisher grade(p=.008) with patients in the high 
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E1 group having higher severity of injury than those in the low E1 group.  L ikewise, patients 
with higher HH (E1 p=.01, E2 p=.02) and Fisher (E1 p=.008, E2 p=.08) were more likely to have 
higher plasma estrogen levels. The presence of DCI was also significantly associated with higher 
levels of plasma E1(p=.002) and E2(p=.03) and the high E1 trajectory group(p=.09). CSF was 
evaluated in 36 aSAH patients. Similar correlations between higher E1 and E2 CSF 
concentrations and severity of injury and DCI were noted. These results provide the first clinical 
evidence that E1 and E2 concentrations in plasma and CSF are associated with severity of injury 
and DCI and provide incentive for future studies to clarify the potential role of estrogen in 
ischemic complications after aSAH. 
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PREFACE 
“If I have seen further it is by standing on the shoulders of giants.” 
Sir Isaac Newton, 1675 
As I reflect back on 3 decades of school and career I am amazed at the where I stand. From the 
time I could remember, I have always wanted to work in healthcare. Almost exactly 30 years ago 
I decided that medical school seemed too long and laborious and so I set off to become a nurse. 
Now all these years later, I stand at the precipice of a different doctoral degree and I realize that 
my lifetime goal has not changed. I want to make a difference in the delivery of care to patients 
and families. To arrive at this achievement I have relied on the direction and support of many 
individuals, faculty, friends, colleagues and family. 
First I must thank God for providing me strength, wisdom and courage. Even when I 
didn’t fully understand the turns in my path or the roadblocks in my way, He has guided me. I 
have never been so completely at His mercy.  I owe an enormous debt of gratitude to the 
members of my dissertation committee who have been mentors, models, teachers, friends and 
advocates. Each one brought unique contributions to this endeavor. I especially want to thank Dr. 
Paula Sherwood for agreeing to be my Dissertation chair. Her tireless patience, support and 
guidance have allowed me to progress to this point. To Dr. Sam Poloyac for being my surrogate 
chair while Dr. Sherwood was in Finland fulfilling her Fulbright Scholarship obligations, for his 
patience in helping me to learn metabolite analysis and for his persistence with perfecting 
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analysis techniques.  I am indebted to Dr. Jeff Balzer for providing his expert knowledge of 
neurological injury and cerebral blood flow and for always challenging my perspective.  To Dr. 
Cathy Bender not only for her insight into Estrogen from years of her own research, but also her 
gentle guidance a mentor and nursing faculty member. And I thank Dr. Ren for his guidance 
during the analysis of these findings.  I look forward to years of collaboration with all of you. 
I would like to express my sincere appreciation to the faculty within the School of 
Nursing for sharing their expertise and wisdom. I would like to thank the subarachnoid 
hemorrhage research team at the University of Pittsburgh, both past and current, for supporting 
and encouraging me through this journey. Dr. Mary Kerr started this team over 10 years ago and 
hired me into this academic environment. I still follow the fundamentals she instilled in me years 
ago.  And I would like to thank the members of the small molecular biomarker core at the School 
of Pharmacy for the patience to teach a nurse how to process and analyze biological specimens. I 
would like to acknowledge the funders of my research, the Neuroscience Nursing Foundation 
and the Nightingale Awards of Pennsylvania who supported this project. 
Finally, and most importantly, I would like to thank my family. My mother as a fellow 
nurse and a beacon of nursing advocacy and leadership. My father, who has never doubted any 
of my accomplishments. And to my husband and children who have endured all of these years of 
school, often when they didn’t understand the demands or the milestones. They have given me 
the opportunity to focus on my professional and academic life even when it took time away from 
them. I count my blessings. 
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1.0  INTRODUCTION 
Aneurysmal subarachnoid hemorrhage (aSAH) is a sudden and devastating neurological event 
affecting approximately 10 in 100,000 persons annually and resulting in significant morbidity 
(30% of survivors) and mortality (12% pre-hospital, 40% within one month of admission) (Cahill 
& Zhang, 2009).  Despite advances in medical and surgical management, aSAH continues to be 
associated with complications which necessitate vigilant monitoring and emergent interventions 
during the acute recovery period (Cahill & Zhang, 2009; Frontera et al.., 2009; Ostrowski, et al.., 
2006; Sehba et al.., 2011; Zubkov & Rabinstein, 2009). Following hospital discharge, many 
patients experience long-term functional and cognitive impairment that impacts the ability of 
patients to resume previously held familial, social and occupational roles (Vergouwen et al.., 
2009). 
Unstable intracranial physiology and systemic medical complications are common after 
aSAH and may influence outcomes (Rose, 2011).  Structural changes such as cerebral edema and 
hemorrhage may occur but do not adequately predict the risk of neurological decline and poor 
outcomes after aSAH (Cahill & Zhang, 2009; Frontera et al.., 2009).  Cerebral vasospasm, or 
vessel narrowing, can result in regional reduction of cerebral perfusion and potential ischemia 
and therefore, has been a primary focus of research and treatment after aSAH (Cahill & Zhang, 
2009; Frontera et al.., 2009; Keryoux & Diringer, 2007; Ostrowski, et al.., 2006 ;  Rose, 2011; 
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Sehba et al.., 2011; Vergouwen et al.., 2011; Zubkov & Rabinstein, 2009). The diagnosis of 
cerebral vasospasm is often based on visualization of the macrovascular circulation using 
cerebral angiography which has inconsistently correlated with neurologic demise, complications 
or long term outcomes period (Cahill & Zhang, 2009; Frontera et al.., 2009; Ostrowski, et al.., 
2006; Sehba et al.., 2011; Vergouwen et al.., 2009; Zubkov & Rabinstein, 2009).   
More recently, delayed cerebral ischemia (DCI) has been implicated as a leading cause of 
complications after aSAH (Vergouwen et al.., 2011).   DCI, which occurs in approximately 20-
60% of patients who survive the initial hemorrhage, (Cahill & Zhang, 2009; Frontera et al.., 
2009; Keryoux & Diringer, 2007; Ostrowski, et al.., 2006; Rose, 2011; Sehba et al.., 2011; 
Vergouwen et al.., 2011; Vergouwen et al.., 2009; Zubkov & Rabinstein, 2009) is thought to be 
the result of a mismatch between available cerebral blood flow (CBF) and metabolic demands of  
brain tissue, a consequence that leads to neuronal changes and neurological decline (Crago et al.., 
2011; Dupont et al.., 2009; Kolias et al.., 2009;  M acdonald et al.., 2008; Vergouwen et al.., 
2011;).  In order to provide early intervention and potentially reverse ischemia, it is important to 
promptly recognize and treat DCI.  H owever, clear clinical indicators of DCI have not been 
identified. While an association between vasospasm, DCI, cerebral infarction and poor outcomes 
has been identified, each may occur independently. Of concern, reduced incidence of 
angiographic vasospasm has not significantly altered the development of ischemic complications 
or improved outcomes(Cahill & Zhang, 2009; Frontera et al.., 2009; Dupont et al.., 2009;  Kolias 
et al.., 2009; Macdonald et al.., 2008; Ostrowski, et al.., 2006; Sehba et al.., 2011; Vergouwen et 
al.., 2011; Vergouwen et al.., 2009;  Zubkov & Rabinstein, 2009).  Further, approximately 50-
70% of aSAH patients have angiographic evidence of cerebral vascular constriction 
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(angiographic vasospasm), but only one third experience symptoms of DCI (Crago et al.., 2011; 
Frontera et al., 2009). 
More recent proposals have theorized that microvascular dysfunction or changes are the 
pathogenesis of DCI (Vergouwen et al., 2009). The origin of these microvascular alterations may 
result from molecular and cellular changes that alter vascular dynamics and cerebral perfusion; 
therefore shifts in vasoactive metabolite levels may provide a marker of ischemic complications 
after neurologic insults (Crago et al., 2011; Macdonald et al., 2008; Ostrowski, et al., 2006; 
Sehba et al., 2011). Research studies have identified an association between higher levels of 
endothelin (ET-1) and cerebral vasoconstriction after aSAH (Macdonald et al., 2008; 
Neuschmelting et al., 2009). In addition, the presence of 20-hydroxyicosatetraenoic acid (20-
HETE), a p otent microvascular vasoconstrictor, has been associated with the development of 
DCI after aSAH (Crago et al., 2011; Imig et al., 2011; Kehl et al., 2002; Roman et al., 2006).  
Conversely, epoxyeicosatrienoic acids (EETs) are potent vasodilators. Inhibition of the enzyme 
soluble epoxide hydrolase (sEH) which metabolizes EETs has been linked to reduction in 
cerebral infarction in experimental studies (Crago et al., 2011; Losiniecki & Zuccarello, 2008; 
Kehl et al., 2002; Imig et al., 2011; Roman et al., 2006). The presence of inflammatory markers 
has been correlated with early brain injury and poor outcomes and glutamate has long been 
associated with apoptosis and neuronal death (Cahill & Zhang, 2009; Frontera et al., 2012; 
Provencio & Vora, 2005; Sehba et al., 2012). Unfortunately, despite extensive research, the 
clinical utility of markers of injury or complications have not been predictive of DCI 
development in these susceptible patients (Cahill & Zhang, 2009; Crago et al., 2011; Sehba et al., 
2012; Sehba et al., 2011).  The absence of a c lear clinical indicator of DCI prevents early 
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detection and effective management of this complication. Hence, a change in focus may be 
necessary to improve outcomes.  
Another biomarker, estrogen, has been widely studied in neurological disorders including 
both experimental ischemic and hemorrhagic insults (Azcoitia et al., 2011; Carwile et al., 2009; 
Herson et al., 2009).  Estrone (E1) is a physiologic estrogen that is the major remaining estrogen 
after menopause. In experimental studies E1 has been related to vascular reactivity and 
vasodilation through nitrous oxide pathways (Gatson et al., 2011; Rauschemberger et al., 2011, 
Selles et al., 2005).   Estradiol (E2) is the most commonly studied neuro-steroid that alters 
vascular reactivity, reduces tissue damage, improves functional recovery and may stimulate 
repair processes (Herson et al., 2009). The absence of E2 has been linked to vasoconstriction, 
impaired cellular metabolism and cellular death in animal models (Brown et al., 2009; Herson et 
al., 2009).  I n humans, increased levels of E2 have been positively correlated with improved 
outcomes in stroke and traumatic brain injured patients (Azcoitia et al., 2011; Brown et al., 2009; 
Carwile et al., 2009; Herson et al., 2009; Krause et al., 2006).  E2 has been associated with a 
number of the markers currently under investigation in SAH research. In preclinical studies, E2 
suppresses soluble epoxide hydrolase (sEH) expression which reduces inflammation, suppresses 
glutamate excitoxicity, potentially preventing cell death, and competes with 20-HETE through 
known mechanical channels to restrict vasoconstriction (Behl, 2002; Ba et al., 2007; Brown et 
al., 2009; Fassbender et al., 2000; Rauschemberger et al., 2011; Sarkar et al., 2008; Zhang et al., 
2009).  Prior research examining E2 and other vasoactive metabolites has involved experimental 
conditions (animal models) or non SAH clinical populations, e.g., traumatic brain injury (TBI), 
stroke and dementia.  There are substantial differences in the pathophysiological basis of injury 
 5 
 
following aSAH compared to these other neurologic insults. No study was identified that 
explored whether changes in estrogen levels may play a role in reducing ischemic complications 
and improving outcomes in patients with aSAH. Therefore, the proposed study will address this 
gap in the knowledge related to the role of E1 and E2 in promoting complications such as DCI in 
aSAH patients. 
1.1 PURPOSE 
The purpose of this study was to examine the association between levels of estrogen (estradiol 
and estrone) and the development of DCI in patients with aSAH.  
1.2 SPECIFIC AIMS 
1. Examine patterns in plasma E1 and E2 levels during the 10 days following aSAH. 
H1: Distinct groups of patients will be identified with varying patterns of plasma E1 and E2 
levels following aSAH. 
2. Determine the relationship between plasma E1 and E2 levels and the presence or absence of 
DCI during the 10 days following aSAH. 
    H1: After controlling for age, gender, menopausal status and severity of hemorrhage, higher 
levels of E1 and E2 will be associated with lower incidence of DCI. 
Exploratory 
3. Examine patterns in CSF E1 and E2 levels during the 10 days following aSAH.  
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 H1: Distinct groups of patients will be identified with varying patterns of CSF E1 and E2 
levels following aSAH. 
4. Determine the relationship between CSF E1 and E2 levels and the presence or absence of 
DCI during the 10 days following aSAH. 
 H1: After controlling for age, gender, menopausal status and severity of hemorrhage, higher 
levels of E1 and E2 will be associated with lower incidence of DCI. 
5. Explore the associations among CSF levels of E1 and E2, 20-HETE and EET a nd the 
presence or absence of DCI following aSAH.  
    H1: Higher levels of E1 and E2 will be associated with higher levels of EETs which will be 
associated with a lower incidence of DCI. 
H2: Higher levels of E1 and E2 will be associated with lower levels of 20-HETEwhich will 
be associated with a lower incidence of DCI. 
1.3 INNOVATION AND SIGNIFICANCE 
The aims of this study address a gap in knowledge related to the role of estrogens in ischemic 
complications such as DCI after aSAH. The proposed study has the potential to significantly 
advance our understanding of the mechanisms underlying the development of DCI, a major 
complication faced by critical care practitioners, and more accurately predict patients at high risk 
for poor outcomes. The study was significant because:  1)  it was the first known study to 
describe the presence of E1 and E2 in plasma and CSF from human aSAH patients and explore 
the association of E1 and E2 to ischemic complications after insult. This innovative step may 
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lead to improved understanding of factors which promote DCI and methods to improve patient 
outcomes. Neither E1 nor E2 has been described in human CSF using HPLC in a moderate or 
large sample; 2) it utilized demographic and sample data from a well-established a SAH research 
program with an existing large bank of human aSAH samples from a highly productive, 
multidisciplinary team of critical care experts. This resource enabled concomitant evaluation of 
findings from bench and bedside research. 3) Finally, analysis of the role of E1 and E2 in 
outcomes following aSAH was conducted concurrently with analysis of other potentially related 
metabolites (20-HETE, EET). Assays for these biomarkers were available from the parent study, 
thereby adding an additional innovative path of analysis to the proposed study. The proposed 
study was the first study to analyze E1 and E2 levels in relation to these other metabolites in 
patients with aSAH. Ultimately, these new data will advance the science for patients with critical 
illness related to aSAH by identifying potential paths for intervention to prevent the cascade of 
events that produces DCI and other adverse patient outcomes. 
1.4 BACKGROUND 
1.4.1 Aneurysmal SAH is the cause of substantial mortality and morbidity 
Aneurysmal SAH (aSAH), which accounts for 5-7% of all strokes, occurs in approximately 1 in 
1000 persons annually at a mean age of 53 years and is more common in females than males 
(Rose, 2011).7 In spite of treatment advances, significant improvement  in morbidity and 
mortality has not been achieved and poor outcomes often occur in survivors (Cahill & Zhang, 
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2009; Diringer et al., 2011).  This acute cerebrovascular event has a devastating effect on the 
central nervous system as well as other organs and is a frequent cause of long-term functional 
and cognitive disabilities (Diringer et al., 2011).  At the time of aneurysm rupture, a sudden rise 
in intracranial pressure triggers the stress response inducing a s urge of circulating mediators 
which, along with blood products in the subarachnoid space, result in impaired cerebral blood 
flow and autoregulation, disruption of the blood brain barrier and the onset of systemic 
complicationssuch as increased blood pressure and cardiopulmonary dysfunction (Ostrowski et 
al., 2006; Sehba et al., 2011). Early aneurysm treatment has reduced re-bleeding; however, 
patients are a risk for delayed complications that lead to cerebral ischemia up to two weeks later. 
This development is believed to be the primary factor in the development of subsequent 
complications (Diringer et al., 2011; Dupont et al., 2009). 
 
1.4.2 Prevention of complications after aSAH remains an elusive goal 
Aneurysmal SAH results when a p athological dilation of a cer ebral artery ruptures releasing 
blood into the subarachnoid space and ventricular system. The subarachnoid blood also results in 
a sudden rise in intracranial pressure which triggers the stress response, induces a surge of 
circulating catecholamines and a subsequent release of arachidonic acid from plasma membranes 
(Cahill & Zhang, 2009; Ostrowski et al., 2006).  Activation of the arachidonic acid cascade 
causes the release of inflammatory and vasoactive mediators (Cahill & Zhang, 2009; Ostrowski 
et al., 2006).  The consequence of vasoactive mediators and the presence of blood products in the 
subarachnoid space result in impaired cerebral autoregulation, global ischemia, apoptosis, 
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necrosis and cellular death (Cahill & Zhang, 2009; Ostrowski et al., 2006; Sehba et al., 2012). 
The consequences of these events are disruption of the blood brain barrier and the development 
of cerebral edema in the early minutes and hours after aSAH (Cahill & Zhang, 2009; Ostrowski 
et al., 2006; Sehba et al., 2012).  The pathologic effects of early brain injury have been suggested 
to impact mortality as well as acute and long term recovery after aSAH (Cahill & Zhang, 2009). 
Historically, structural changes, primarily cerebral vasospasm, have been considered the 
primary cause of clinical decline after aSAH. Cerebral vasospasm is the narrowing of cerebral 
arteries which may or may not result in diminished perfusion to tissues distal to the affected 
blood vessels (Cahill & Zhang, 2009; Ostrowski et al., 2006; Sehba et al., 2012; Sehba et al., 
2011).  Traditionally, vasospasm has been diagnosed by visualization of the macrovascular 
circulation using radiologic techniques, primarily digital subtraction angiography. The risk of 
cerebral vasospasm peaks between 5 and 15 days after hemorrhage although it has been reported 
earlier and is associated with the severity of hemorrhage following aSAH (Dupont et al., 2009). 
Vascular constriction may occur in one or multiple arteries and ranges from mild to severe in 
degree of narrowing. If vasoconstriction along with impaired autoregulation result in blood flow 
that is below the ischemic threshold, symptoms of neurologic compromise will ensue (Keyroux 
& Diringer, 2007). Clinical evidence has demonstrated that up to 70% of aSAH patients have 
angiographic evidence of vascular constriction known as angiographic vasospasm, while most 
studies report only 20-30%experience symptoms of neurologic deterioration (Dankbaar et al., 
2011; Frontera et al., 2009; Vergouwen et al., 2011a; Vergouwen et al., 2011b;  Z ubkov & 
Rabinstein, 2009).  Basic and clinical research have focused on predicting and treating cerebral 
vasospasm based on the hypothesis that vasospasm leads to DCI and consequently poor 
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outcomes as a result of additional ischemic injury; evidence is inconclusive regarding how this 
finding links to DCI or recovery.  
These findings have led to a r eexamination of theories regarding causality and patient 
outcomes following aSAH.  In a recent study of 413 SAH patients of whom 194 had moderate to 
severe vasospasm, only 43% exhibited signs of neurological worsening, 20% had cerebral 
infarction and 46% had a poor outcome (Vergouwen et al., 2011b).   In this same cohort, path 
analysis revealed that only cerebral infarction had a d irect effect on outcome which was 
independent of angiographic vasospasm. Results of the CONSCIOUS-1 clinical trial also support 
this incongruity; prevention of cerebral vasospasm did not result in reduction of DCI or 
improvement in outcomes (Vergouwen et al., 2011a).  Consistent with findings of these studies, 
the majority of clinical evidence appears to implicate other factors in the pathogenesis of DCI 
including those that result in microvascular dysfunction and changes. 
DCI, a c oncept focused on insufficient blood flow, has become the primary outcome 
target in aSAH studies.  DCI, defined as cerebral ischemia that occurs in the days after aSAH 
(Vergouwen et al., 2011b),  a ffects up to two thirds of the patients who survive aSAH and is 
considered the leading cause of morbidity and mortality (Frontera et al., 2009; Kolias et al., 
2009). DCI, which occurs when cerebral blood flow is inadequate to meet cerebral metabolic 
demand, is manifested by neuronal changes and neurologic decline from inadequate blood 
supply to the cerebral tissue. DCI is most likely to occur 3-14 days after the initial bleeding, 
which may allow sufficient timing for therapeutic intervention; however clear clinical indicators 
of DCI have not been identified (Frontera et al., 2009; Vergouwen et al., 2011a; Vergouwen et 
al., 2011b; Zubkov & Rabinstein, 2009). While an association exists between vasospasm, DCI, 
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cerebral infarction and poor outcomes after aSAH, each has also been described independently 
Dankbaar et al., 2011; Vergouwen et al. 2011a). 
Clinical care for aSAH patients is targeted at preventing or controlling complications 
with standard treatment protocols that include serial neurological exams, blood pressure control, 
fluid management, medications (calcium channel blockers, magnesium sulfate and statins), and 
HHH therapy (hypertension, hypervolemia, hemodilution) (Diringer et al., 2011; Rose, 2011; 
Sehba et al., 2011).  Following aSAH, patients require extensive critical care resources and 
monitoring in an attempt to prevent and control both intracranial (cerebral vasospasm, edema, 
ischemia and increased intracranial pressure) and systemic complications (fever, 
cardiopulmonary compromise and anemia) (Diringer et al., 2011; Rose, 2011; Sehba et al., 
2011).  Unfortunately despite standardized practices, marked improvement in outcomes has not 
occurred and the rate of ischemic complications including DCI remains high (Diringer et al., 
2011; Rose, 2011; Sehba et al., 2011; Vergouwen et al., 2011). 
1.4.3   Potential additional explanations for this complication  
The limited success of vasospasm-directed trials in reducing delayed ischemic injury or 
improving outcomes has led investigators to seek other explanations for ischemic complications. 
Injury to internal structures of the brain tissue, vasculature and cells as a co nsequence of the 
hemorrhage and the sudden rise in intracranial pressure may precipitate other mechanisms 
associated with early brain injury (Ostrowski et al., 2006; Sehba et al., 2011). These mechanisms 
include molecular, cellular, vascular, and ionic changes that effect intracranial processes and loss 
of cerebral autoregulation and vascular stability.  In particular, biochemical changes that alter the 
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balance of vasoactive metabolites may influence microvascular vasosconstriction and 
development of ischemic complications following acute neurological insult (Ostrowski et al., 
2006; Sehba et al., 2011).  Nitric Oxide (NO), inflammatory markers, catecholamines, endothelin 
(ET-1), 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EET’s) are 
among the metabolites that have been associated with regulation of vascular stability after aSAH.  
The release of hemoglobin into the subarachnoid space creates multiple chemical changes 
that are implicated in reduced cerebral blood flow and ischemia (Ostrowski, 2006).  Initially, 
hemoglobin scavenges NO, eliminating its vasodilatory effects in cerebral autoregulation 
(Ostrowski, 2006). Inflammatory markers are released remotely in response to both global 
ischemia and the release of vasoactive compounds such as platelets at the time of hemorrhage. 
Both parenchymal and vascular inflammation follows 48 h ours after ictus which has a 
compounding effect on apoptotic cell death. Elevations in inflammatory markers have been 
confirmed in the plasma and CSF of aSAH patients (Naredi et al., 2006; Provencio & Vora, 
2005). Blood clot is also implicated in the generation of secondary spasmogens including 
catecholamines and 5-HT which have been implicated in vasoconstriction alone and in 
conjunction with other metabolites such as 20-HETE (Ostrowski, 2006).  Extracellular glutamate 
rises dramatically after hemorrhage and is considered a robust marker of ischemia (Ostrowski et 
al., 2006; Sehba et al., 2011).  Glutamate may also propagate from extravasated blood, further 
escalating its concentration and contributing to neuronal death (Ostrowski et al., 2006; Sehba et 
al., 2011).  E T-1 is released from cerebral arteries in response to vascular injury reducing 
sodium/potassium ATPase activity and has been described as a potential mediator of cerebral 
vasospasm (Fassbender, 2000; Neuschemberger et al., 2008; Ostrowski et al., 2006; Sehba et al., 
2011). Clinical research studies have found increased ET-1 levels in CSF of aSAH patients with 
 13 
 
cerebral vasospasm and accordingly administration of an ET-1 antagonist has effectively reduced 
the occurrence angiographic vasospasm.  M olecular, cellular, vascular, and ionic changes 
influence microvascular vasosconstriction and ischemic complications following acute 
neurological insult (Ostrowski et al., 2006; Sehba et al., 2011). 
1.4.4 Estrogen may facilitate vascular stabilization 
Estrogens have been widely studied in neurological disorders including both experimental 
ischemic and hemorrhagic insult models (Brown et al., 2009; Herson et al., 2009; Hurn & Brass, 
2003; Rauschemberger et al., 2008).  T he observation of gender differences along with 
differences between pre- and post-menopausal females and outcomes in both clinical and 
experimental brain injury sparked much of the interest in estrogen (Brown et al., 2009; Herson et 
al., 2009; Hurn & Brass, 2003; Gilles & Mcarthur, 2010; Krause et al., 2006).   Estrone (E1) is a 
physiologic estrogen that is the major remaining estrogen in the circulation after menopause. E1 
is converted to estrone sulfate which serves as a r eservoir for E2 conversion.  I n experimental 
studies E1 has been related to vascular reactivity and vasodilation through nitrous oxide 
pathways (Gatson et al., 2011; Rauschemberger et al., 2011, Rauschemberger et al., 2008; Selles 
et al., 2005).  While the role of E1 in neurological insults has not been described, experimental 
vascular studies have shown thatE1 has both a positive effect on NO synthesis and COX 
activation (Selles et al., 2005; Rauschemberger et al., 2008) as well as having potential 
modulating effects on cellular endothelial growth and survival including production, 
proliferation, apoptosis and cell adhesion events (Rauschemberger et al., 2008). 
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Estradiol (E2) is a neuro-steroid that may facilitate vascular stabilization. E2 alters 
vascular reactivity, reduces tissue damage, improves functional recovery and may stimulate 
repair processes (Brown et al., 2009; Herson et al., 2009; Krause et al., 2006). In preclinical 
studies, female animals suffered less tissue damage than males after both ischemic and traumatic 
insults (Alkayed et al. 1998; Auriat et al., 2005; Gilles & Mcarthur, 2010)   Of additional interest, 
benefit was lost in reproductively senescent or ovarectomized animals, but restored with estrogen 
supplementation (Gilles & Mcarthur, 2010).   In animal studies, estrogen supplementation 
consistently improved functional outcomes after ischemic injury (Alkayed et al. 1998; Auriat et 
al., 2005; Brown et al., 2009; Gilles & Mcarthur, 2010; Kehl et al., 2002; Sribnick et al., 2009).  
In an experimental animal model, the administration of E2 after aSAH resulted in significantly 
less (p<.05) basilar artery spasm and apoptosis manifested by DNA fragmentation when 
measured 7 da ys after insult (Alkayed et al., 1998). Likewise, Yang reported reduction in 
mortality (p=.01) and secondary ischemic damage from improved blood flow (p=.012) in an 
aSAH animal model (Yang et al., 2001).  This effect was also noted in male animals treated with 
E2 administration after intracranial hemorrhage (p=.05) (Alkayed et al., 1998). 
There have been relatively few studies investigating the role of E2 in human subjects; 
however results have supported the hypothesis that E2 has positive effects on cerebral blood flow 
and improved cognitive outcomes. In a study of 24 healthy post-menopausal women, the 
administration of intranasal estrogen resulted in significant increases in cerebral blood flow 
(p<.05) in all regions of interest by SPECT (Kaya et al., 2008).  As a p otential biomarker, 
increased levels of E2 have been correlated with improved outcomes in stroke (less delayed 
ischemia; p<.05) and traumatic brain injured patients as well as neuro-degenerative and aging 
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 It is important to note that recent studies have questioned existing scientific evidence that 
would lead us to believe that higher levels of E2 are beneficial to outcomes related to vascular 
and neurological insults.  K aufmann reported that higher admission E2 levels and to a more 
significant degree changes in E2 levels during critical illness were independently associated with 
mortality (CI 1.1) in addition to other markers of stress response (Kauffman et al., 2011). 
Likewise, higher plasma estradiol levels were found to be associated with higher all-cause and 
non-cardiovascular mortality in a study of 2078 older men referred for coronary angiography 
however these levels were associated with other risk factors for mortality such increased BMI 
(Lerchbaum et al., 2011).  Finally, Wagner et al. reported significantly altered hormonal levels in 
acute male and female severe traumatic brain injured patients however their findings indicated 
acute mortality was associated with the high plasma estradiol trajectory group (p<.01) (Wagner 
et al., 2011).  The results of these studies support an association between critical illness and 
estrogen levels and provide important considerations to consider when exploring the impact of 
estrogen levels on outcomes after aSAH. 
Other than overall incidence of aSAH, investigation of gender influence on aSAH has 
been limited. One study of 163 SAH patients explored predictors of angiographic vasospasm and 
noted significantly less cerebral vasospasm in women (p=.04) in univariate analyses which 
remained a trend in a multivariate logistic regression model (p=.07) along with scales of injury, 
smoking (p=.02) and hydrocephalus (p=.04) (Dupont et al., 2009).  A second study that reviewed 
over 29,000 hospital admissions related to acute brain disorders of which 1029 were diagnosed 
with SAH, noted that male patients had higher incidence of in hospital death (OR 1:1.61, 
p=.001), although specific sources for this finding were not explored (Macleod & Andrew, 
2002).  No gender differences were noted in a s tudy by Orbo and colleagues which evaluated 
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cognitive impairment one year after surgical management in 44 aSAH patients (Orbo et al., 
2008).  Evidence that estrogen alters vascular reactivity, reduces tissue damage, improves 
functional recovery and may stimulate repair processes following experimental and clinical 
neurological insults along with differences in outcomes by gender further substantiates the need 
to explore the role of estrogen  and DCI after aSAH. 
1.4.5 Estradiol neuroprotection may be associated with other metabolites 
The potential mechanisms of estradiol afforded neuroprotection have been associated with a 
number of the markers currently under investigation in SAH research primarily through 
molecular interactions that promote vasodilation.  E2 inhibits ET-1production (p<.05) (Brown et 
al., 2009) which has been a targeted vasoconstrictor in clinical trials (Macdonald et al., 2008; 
Vergouwen et al., 2011a).  E2 may help vascular stabilization by potentiating NO via eNOS and 
iNOS expression (p<.01) (Alkayed et al., 1998; Sabri et al., 2011), reducing apoptosis by 
blocking glutamate, and reducing inflammatory cytokines by suppressing sEH and excitatory 
metabolites (catecholamines) (Brown et al., 2009; Herson et al., 2009; Krause et al., 2006; Zhang 
etal, 2009). 
Another area of influence may be within the cyp450 pathway which is activated through 
the arachidonic acid cascade after neurological insult (Crago et al., 2011; Imig et al., 2011; 
Losniecki & Zuccarello, 2008).    Current evidence suggests that metabolites of arachidonic acid 
form products to regulate cerebral blood flow (Imig et al., 2011).  The hydroxylated metabolite 
20-hydroxyeicosatetraenoic acid (20-HETE) is a vasoconstrictor while epoxygenated metabolites 
or epoxyeicosatrienoic acids (EET’s) are vasodilators. 20-HETE is formed by enzymes of 
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CYP4A and 4F families via ω-hydroxylation of arachidonic acid (AA) in cerebral arteries 
(Rejdak et al., 2004; Roman et al., 2006).  S timulated by angiotensin II, endothelin and 
norepinephrine; 20-HETE is a potent microvascular vasoconstrictor including cerebral vascular 
beds.  There is also evidence that 20-HETE plays an important role as an oxygen sensor in the 
microcirculation. Pre-clinical and clinical evidence has implicated 20-HETE in changes in the 
cerebral vascular tone including the development of delayed cerebral vasospasm and ischemia 
(Crago et al., 2011; Roman et al., 2006).  Administration of inhibitors of 20-HETE synthesis and 
20-HETE antagonists have been shown to reverse delayed vasospasm and prevent acute 
decreases in CBF (Omura et al., 2006;Poloyac et al., 2006;  Yu et al., 2004). Likewise, inhibition 
of 20-HETE formation was found to be neuroprotective in a temporary focal ischemia SAH 
animal model (Poloyac et al., 2006)  a nd attenuated the post-injury CBF that typically 
accompanies ischemic and hemorrhagic stroke (Poloyac et al., 2005).  Although 20-HETE is a 
potent microvascular constrictor, it has little or no effect on larger arteries (Roman et al., 2006). 
More recently, elevated levels of 20-HETE in CSF and plasma have been reported in a small 
number of aSAH patients with documented evidence of cerebral vasospasm and neurological 
deficits (Crago et al., 2011).  Clinical evidence from our work showed a significant relationship 
between the presence of 20-HETE in cerebral spinal fluid and the presence of DCI (Crago et al., 
2011).   In 108 acute aSAH patients, the presence of detectable 20-HETE levels were observed in 
31% of patient samples and were associated with severity of hemorrhage (p=.04) and DCI 
(p=.016) (Crago et al., 2011).   E 2 inhibits 20-HETE pathways of vasoconstriction through 
known channels (p<.001) (Ba et al., 2007; Be, 2002; Brown et al., 2009; Rauschemberger et al., 
2011; Sarkar et al., 2008; Zhang et al., 2009),  diminishing  t he influence of 20-HETE on 
vasoconstriction. 
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Conversely, EETs are considered sensors of neuronal activity that may enhance 
functional hyperemia (Illif et al., 2009; Imig et al., 2011).  EETs are potent vasodilators  and 
important regulators of vascular function that are synthesized from arachidonic acid by  
cytochrome P-450 epoxygenase enzymes of the CYP2C and Cyp2J families (Illif et al., 2009).  
In addition to their vasodilatory role, clinical studies have identified EETs as possessing anti-
inflammatory, anti-thrombotic, fibrinolytic, angiogenic, anti-apoptotic and anti-oxidant 
properties (Illif et al., 2009). EETs are released from astrocytes and vascular endothelium in the 
brain in response to glutamine release. The EETs dilate cerebral arteries through activation of K+ 
channels and recruit blood flow to the active areas of the brain (Illif et al., 2009; Roman et al., 
2006).  EETs are rapidly degraded by soluble epoxide hydrolase (sEH) into 
dihydroxyeicosatrienoic acids (DHETs). Likewise sEH is responsible for converting EpOMEs to 
DiHOME’s which are also surrogate measurements for EETs (Crago et al., 2011; Illif et al., 
2009; Roman et al., 2006).  E2 suppresses sEH which increases the availability of EETs which 
have been identified as vasodilators (Zhang et al., 2009).  In experimental studies inhibition of 
sEH has resulted in smaller infarct size after experimental stroke (Zhang et al., 2009). 
The premise of this study is that these molecular alterations are thought to be a primary 
cause of vascular constriction in the microcirculation which may precipitate ischemia that results 
in prolonged and more profound consequences. Clinically small vessel ischemia may not be 
detected during cerebral angiograms and may be responsible for neurological decline in the 
absence of radiographic vasospasm (Vergouwen et al., 2009).  Vascular stability after aSAH is 
dependent upon a balance in the brain between metabolites that cause vasoconstriction (ET-1 and 
20-HETE) and those that cause vasodilation (EETs and Nitrous Oxide). If the equilibrium is 
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maintained after insult, there is a low risk of DCI. However if equilibrium is not maintained, the 
risk of DCI is increased.  
The potential influence of estrogen on these more established vasoactive markers that 
impact cellular and vascular response after aSAH deserves further attention. Evidence of the 
actions of E2, and to a lesser degree E1, in animal models and research exploring its mechanisms 
of action in other neurologic conditions provide a strong rationale for the significance of the 
proposed study which will explore the relationship between plasma E2 levels and ischemic 
complications after acute aSAH in humans. This evidence provides support for the framework 
for this study which includes the potential effect E2 may have on the vascular changes that occur 
after aSAH depicted in Figure 1. 
1.4.6 Conceptual Framework 
 
Figure 1.Conceptual Framework 
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1.5 RESEARCH METHODS 
1.5.1 Design 
This study used a prospective, longitudinal design to examine E1 and E2 levels in plasma and 
cerebral spinal fluid (CSF) and ischemic outcomes (DCI) in patients with acute aSAH. 
1.5.2 Setting  
The study was a secondary analysis of data from patients with acute aSAH admitted to the 
neurovascular intensive care unit at the University of Pittsburgh Medical Center (UPMC) 
Presbyterian Hospital who were enrolled in a NIH-funded study (R01NR004339) exploring the 
influence of biomarkers related to complications of aSAH.  UPMC comprises a network of 20 
hospitals, servicing the health needs of over 4 million people. UPMC Presbyterian is an 800-bed, 
designated Level I Regional Resource Trauma Center with over 24 specialty services. UPMC 
Presbyterian contains 10 intensive care units including a 20 bed neurovascular intensive care unit 
that provides care to persons with a broad spectrum of neurovascular insults; 14% of their 
admissions are persons with aSAH. The internationally renowned Department of Neurological 
Surgery, started more than 60 years ago, is one of the largest neurosurgical academic providers 
in the United States; more than 6,500 procedures are performed annually through the department.  
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1.5.3 Sample  
This study used data from 99 acute aSAH patients consecutively selected from the database of 
the previously cited NIH study (RO1NR004339). At the time of this analysis, 350 subjects had 
been recruited. 
1.5.3.1 Participant Recruitment for the Parent Study  
Inclusion criteria for the parent study were: 1) 21-75 years; 2) verified aneurysmal SAH; and 3) 
Fisher grade > 1 (determined by evidence of blood on CT scan). Confirmation of aneurysm was 
verified by cerebral angiography or CT angiogram read and interpreted by a n eurosurgeon. 
Exclusion criteria were: 1) non aneurysmal SAH; and 2) history of preexisting debilitating 
neurologic disease and 3) mycotic aneurysm.  Potential patients were identified by physician or 
nursing staff involved in the care of the patient and permission was established for the study 
team to approach the patient and/or family. Procedures, risks and benefits were explained to the 
patient and/or family and consent was obtained. When necessary, both surrogate and proxy 
consent using Pennsylvania state law guidelines were used due to the cognitive dysfunction 
common in acute aSAH patients. When possible, assent or patient consent was obtained; if not, 
consent for continued participation was obtained when the patient was able to understand and 
provide consent. The protocol was approved by the Institutional Review Board and informed 
consent was obtained from the patient or proxy prior to data collection (Appendix A). The 
consent allows use of samples for analyses determined to be potentially useful by the research 
team. 
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1.5.3.2 Dissertation Study 
The sample for the dissertation analysis was selected from the database of the parent study in 
consecutive order based on availability of outcome data and biologic specimens. Only patients 
with a minimum of 3 available plasma and corresponding CSF samples were included. The 
sample was stratified to include women (both pre- and postmenopausal) and men without 
statistical differences in severity of injury or incidence of DCI. Females on oral contraceptives or 
estrogen replacement were excluded from the analysis. Age was not statistically different 
between males and females with the exception of pre and postmenopausal female groups. 
 
Figure 2. Study Consort 
Rationale: To permit examination of the variables of interest related to the outcome of DCI 
while controlling for differences in age, gender, severity of injury and menopausal status.    
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1.5.3.3 Sample Size 
Data from 99 aSAH subjects with DCI and biomarker information was used in this analysis. 
Rationale: There are no known studies that have analyzed E1 and E2 levels in human aSAH 
patients. To achieve study aims, it was judged necessary to control for age, gender and menopausal 
status as well as confounding variables related to severity of injury (HH and Fisher grade). The 
proposed sample size was also based on consideration of the incidence of DCI which, in a previous 
analysis in this sample, was approximately 50 percent. A logistic regression of the binary response 
variable DCI(Y) on a continuous, normally distributed E2 variable (X) with a sample size of 100 
observations (patients with the dependent variable DCI) achieves 80% power at a .05 significance 
level to detect a change in probability (Y=1) from the value of .5 at the mean of X to .643 when X is 
increased to one standard deviation above the mean. This change corresponds to an odds ratio of 
1.799.  An adjustment was made since a multiple regression of the independent variable of interest 
on the other independent variables in the logistic regression obtained an R-Squared of .09 (Hseih et 
al., 1988).  A Cox regression of the log hazard ratio on a covariate with a standard deviation of 1.23 
based on a sample of 100 observations achieves 90% power at a .05 significance level to detect a 
regression coefficient equal to .3907 and hazard ratio of 1.48. The sample size was adjusted since a 
multiple regression of the variable of interest on the other covariates in the Cox regression is 
expected to have an R-Squared of .09. The sample size was adjusted for an anticipated event rate 
(DCI) of .5 (Hseih & Lavori, 2000; Schoenfeld, 1983). 
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1.5.4 Study Variables 
1.5.4.1 Demographics (Co-variates) 
 Basic demographic information including severity of injury, aneurysm information, age (in 
years), race, gender, past medical history and menopausal status was inpatient medical records. 
Past medical history including menopausal status were obtained from the patient, family or 
medical record. Severity of injury [Hunt and Hess scores (HH) and Fisher grades] and aneurysm 
information were obtained from the neurosurgical notes in the patient’s clinical record. 
 
1.5.4.2 Estradiol and Estrone (Independent variables) 
E1 and E2 were measured in plasma and CSF samples of each aSAH patient and analyzed as a 
ratio scaled, continuous variable. Each morning (8am +/- 1 hour) and evening (7pm +/- 1 hour) 
through 10 days after initial hemorrhage, blood and CSF were collected as part of the parent 
study protocol. At each time point, a blood sample was gathered in an EDTA tube and 
centrifuged. The plasma was aliquoted and frozen for analysis within 60 minutes of collection. 
CSF was withdrawn by registered nurses directly from the CSF tubing as long as the CSF access 
remained in place. Specimens were immediately frozen and stored at -80 degrees for batch 
analysis. In order to capture changes in circulating estrogen levels, at least 3 plasma samples per 
subject were analyzed for E1 and E2 including the initial (first) sample, a sample from day 5-day 
7, and day 10 after hemorrhage. For CSF, E1 and E2 was analyzed in 3-5 samples per subject 
including a sample from the initial (first) sample, a sample from day 5 through day 7, and day 10 
after hemorrhage. E1 and E2 were assayed at the University of Pittsburgh Small Molecule 
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Biomarker Core, using liquid chromatography-tandem mass spectrometry (LC-MS/MS). LC-
MS/MS is a preferred method to measure E2 among postmenopausal women given its high 
sensitivity at low postmenopausal E2 concentrations, which are often below the sensitivity of 
standard immunoassays. The UPLC-MS/MS method employs liquid-liquid extraction, 
derivatization and detection with a t riple quad mass spectrometer.  Plasma and CSF is spiked 
with n-butyl chloride, derivatized with dansyl chloride and transferred to autosampler glass vials 
for injection. E2 is eluted from a Waters Acquity UPLC BEH C18, 1.7 um, 2.1x150 mm 
reversed-phase column, with an acetonitrile: water (0.1% formic acid) gradient. Detection and 
quantitation are achieved in the positive mode with a Thermo Fisher TSQ Quantum Ultra mass 
spectrometer interfaced via an electrospray ionization (ESI) probe with the Waters UPLC 
Acquity solvent delivery system.  Transitions used for analysis are 506 --> 171 for estradiol, 504 
 171 for estrone, and 511 --> 171 for the deuterated internal standard. The calibration curves, 
obtained from extracting known concentrations of E2 from 2-hydroxypropyl-beta-cyclodextrin 
(0.2% in water), range from 0.5 pg/ml (lower limit of quantitation) to 200 pg/ml. The calibration 
curves, obtained from extracting known concentrations of E1 from 2-hydroxypropyl-beta-
cyclodextrin (0.2% in water), range from .5 pg/ml (lower limit of quantitation) to 200 pg/ ml.  
The limit of detection is 0.5 pg/ml.  All back calculations of calibrators, inter-day and intra-day 
precision and accuracy, and stability are within acceptable limits (<15% at all tested 
concentrations) (Nelsen et al., 2004). 
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1.5.4.3 DCI (Dependent Variable) 
Measurements of DCI were evaluated from admission through the 10th day after aSAH (or 
discharge from the acute care setting) and operationalized as evidence of impaired cerebral blood 
flow (cerebral vasospasm by angiography or transcranial Doppler, cerebral ischemia or cerebral 
infarction via CT or MRI brain/perfusion scan) accompanied by neurological deterioration 
(simultaneously or within 12 hours pre or post visualization of impaired cerebral blood flow). 
Neurological deterioration was defined by the presence of any of the following: at least a 2 point 
increase in National Institute of Health Stroke Scale (NIHSS) and or decline in Glasgow coma 
score (GCS);  deterioration in pupil reaction; nursing documentation of a focal deficit (visible 
weakness or difficulty speaking); or nursing documentation of a decline in level of consciousness 
(lethargy, agitation, confusion) not associated with fever or medication administration (such as 
sedatives, paralytics or anti-anxiety medications).  T he NIHSS, which was routinely measured 
twice a d ay by the NV-ICU nurse as part of standard of care, is widely used to quantify 
neurologic deficits using a 42 point scale (0=no neurologic deficits) and has shown high inter-
rater reliability and criterion validity (Lyden et al., 1999).  In addition, routine care for aSAH in 
the NV-ICU included documentation of neurological assessments (including GCS) every one to 
two hours. The GCS has a r eported sensitivity of 79-97% and specificity of 84-97% (Prasad, 
1996; Zeucher et al., 2009). 
Cerebral blood flow was assessed by cerebral angiography, transcranial Doppler and CT 
or MR perfusion scans. Although not quantitative, cerebral angiography serves as a method for 
assessing blood flow and was used to evaluate the presence or absence of angiographic 
vasospasm. Cerebral angiograms (ordered as standard of care or in situations of potential 
deterioration) were examined and coded by neurosurgeons blinded to participant identity and 
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dichotomized as either ‘negative’ (0-24% narrowing of cerebral blood vessels) or ‘positive’ 
(>25% narrowing of cerebral blood vessels). Daily transcranial Dopplers were evaluated for 
abnormal flows using a systolic middle cerebral artery velocity > 200 ml/sec and/or a Lindegaard 
ratio > 3.0 (Frontera et al., 2009; Zubkov & Rabinstein, 2009). Transcranial Doppler ultrasounds 
were performed daily for 14 days provide a real-time indicator of presence of vessel narrowing 
by using reflected gated ultrasound waves at 2MHz to determine velocity of the red blood cells 
within the cerebral arteries. Sensitivity of TCD ultrasound has been reported between 84% and 
85.7% with specificity between 89% and 100%, data which indicates that TCDs provide a 
reasonable assessment of blood flow (Kirkness, 2005).  Finally, head CT/MR and head CT/MR 
perfusion scans (ordered a patient care or follow up) were reviewed for the presence/absence of 
new ischemia, infarction or low blood flow (documentation of low, delayed, asymmetric or 
absent blood flow) in the absence of hydrocephalus or rebleed (Ito et al., 2005).  The 
combination of these blood flow measures and neurological deterioration provide a more 
definitive measure of flow-metabolism mismatch. Patients were categorized as a nominally 
scaled binary variable “yes” or “no” for DCI based on the presence or absence of the criteria 
described. For time-dependent analysis all patients were be assigned a ratio-scaled time to event. 
In patients who developed DCI, this time corresponded to the time of DCI criteria. In patients 
who did not develop DCI, time to event was recorded as 340 h ours, which is the end of the 
monitoring period for the parent study. If a patient died prior to the end of the monitoring period 
or DCI, time of death was used as a censoring event. 
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1.5.4.4 Biomarkers 
20-HETE levels in CSF collected in an identical manner and at the same time points as the 
samples used for E2 examination were analyzed as ratio-scaled, continuous variables. 20-HETE 
and EETs were analyzed as a part of the parent grant using a published solid phase extraction 
procedure with minor modifications (Miller et al., 2009).  Modifications included using a sample 
load of 2.0-3.0ml and reconstituting the samples in 50μl of 80:20 methanol/water. Quantitation 
of CYP-eicosanoids was performed using a published ultra-performance liquid chromatography 
with tandem mass spectrometry (UPLC-MS/MS) method (Miller et al., 2009).  Briefly, liquid 
chromatography was performed using a UPLC BEH C18, 1.7µm (2.1 x 100mm) reversed-phase 
column (Waters, Milford, MA).  M ass spectrometric analysis of analyte formation was 
performed using a T SQ Quantum Ultra (Thermo Fisher Scientific, San Jose, CA) triple 
quadrupole mass spectrometer. Quantitation of analytes by selective reaction monitoring SRM 
analysis was performed by monitoring their m/z transitions. The SRN conditions for these 
molecules and their retention times are shown in Table 1. 
 
 
Table 1. UPLC-MS/MS Method Parameters for Analytes 
Analytes 
Precursor→ Product  
(m/z) 
Collision 
Energy (V) Retention Time (min) 
20-HETE 319→ 245,289 18 3.48 
14,15-DHETE 337→ 207 15 3.01 
11,12-DHETE 337→ 167 14 3.19 
9,10-EpOME 295→227 18 4.43 
9,10-DiHOME 313→201 22 2.89 
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1.5.5 Data Collection 
A total of 99 subjects with aSAH and biologic samples were selected for inclusion in this study. 
Convenience sampling was used to select the first males, post-menopausal females and pre-
menopausal females from database of the parent study based on availability of outcome data and 
biologic specimens (minimum of 3 available plasma and corresponding CSF samples) without 
statistical differences in severity of injury or incidence of DCI. Age was not statistically different 
between males and females with the exception of pre and postmenopausal females. Demographic 
and medical condition data was extracted from the inpatient medical record. Data relating to 
biomarkers (with the exception of E1 and E2) was also obtained from this database. Analysis of 
E1 and E2 specimens was performed for the present study. All  p lasma and CSF samples 
collected as a part of the parent study (see appendix) were analyzed using standard procedures 
and samples maintained in a –80oC freezer.  
  
 
 
Table 2. Collection Procedure 
 Collection Day Chart Review 
 1 2 3 4 5 6 7 8 9 10  
Demographics           X 
DCI           X 
Plasma E1&E2 X    X     X  
CSF E1& E2 X  X  X  X  X   
CSF HETE & EET X  X  X  X  X   
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1.5.6 Data Analysis 
1.5.6.1 Preliminary Analysis 
All statistical analyses were preceded by detailed descriptive analysis of the data, using standard 
descriptive summaries (e.g., means, standard deviation, percentiles, ranges and frequencies) and 
graphical techniques (e.g., histograms, scatter plots). In addition, the distributions of all key 
variables were examined to ensure that proposed modeling techniques were suitable. Univariate 
analyses were used to determine associations between outcome variables and key covariates, 
followed by multivariable analysis. Patterns of missing data were reviewed to assess potential 
biases and possible model assumption violations.  
 
1.5.6.2 Data Analysis Aims 1 and 3 
The goal of Specific Aims 1and 3 was to examine patterns in plasma and CSF E1 and E2 levels 
during the 10 days following aSAH. Detailed descriptive statistics for E1 and E2 levels in plasma 
and CSF were reported first. Since there are repeated measures of E1 and E2 level for each 
subject over the first 10 days after SAH, group-based trajectory analysis (Nagin & Odgers, 2010; 
Nagin, 2005) was used to identify the distinct short-term patterns (homogeneous latent trajectory 
classes) of E1 and E2 from day 1 to day 10 after initial hemorrhage. Group based trajectory also 
controls for missing data and inconsistent data points. The different trajectory models were then 
tested and compared based on model selection including entropy which quantifies the uncertainty 
or variability in a system as well as statistical significance, the Bayesian Information Criterion 
(BIC), Akaike’s Information Criterion (AIC) and the substantive utility of the classes (e.g. 
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distinctiveness of the trajectories, proportion assigned to a given class) to determine the optimal 
solution for the number of trajectory groups.  
 
1.5.6.3 Data Analysis Aims 2 and 4 
For Specific Aims 2 and 4, we sought to determine the relationship between plasma and CSF E1 
and E2 levels and the presence or absence of DCI during the 10 d ays following aSAH. First, 
weighted and non-weighted chi-square test and/or Fisher exact test were used as appropriate to 
explore the association between presence of DCI and the different trajectory classes identified in 
specific aims 1 a nd 3 for E1 and E2 in the first 10 da ys after SAH.  T hen multiple logistic 
regression models (GENMOD and PROC MIXED, SAS 9.2) were conducted to evaluate the 
relationship between them controlling for possible covariates such as demographic 
characteristics (age, gender, menopausal status and severity of hemorrhage).  
 
1.5.6.4 Data Analysis Aims 5 
For Specific Aim 5, we explored the associations between CSF levels of E1 and E2, 20-HETE 
and EET and the presence or absence of DCI following aSAH. Multiple logistic regression 
models were conducted using SAS v9.2 to evaluate the relationship between these metabolites 
controlling for possible covariates such as demographic characteristics (age, gender, menopausal 
status and severity of hemorrhage).  
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1.6 HUMAN SUBJECTS 
1.6.1 Human Subjects  
The study was a secondary analysis of data from patients with acute aSAH admitted to the 
neurovascular intensive care unit at UPMC Presbyterian Hospital who were enrolled in the 
previously cited NIH-funded study (R01NR004339) exploring the influence of biomarkers 
related to complications of aSAH.  In addition to CSF and plasma samples for metabolite 
measurement, demographic and clinical data were extracted from the research record. All study 
data were stored in locked filing cabinets and managed on secure, password-protected databases 
stored on password protected servers. All patient samples were stored in locked freezers at the 
University of Pittsburgh School of Nursing. 
 
1.6.1.1 Protection of Human Subjects 
The parent study, which included the use of samples for future analysis in studies performed by 
the research team, was approved by the Institutional Review Board of the University of 
Pittsburgh (Appendix A). 
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1.6.2 Source of Materials 
Patient information including demographic, medical history, clinical information and related 
metabolite data were obtained from the parent study database (Appendix B). Stored frozen blood 
and CSF samples, collected as part of the parent study protocol, were obtained for E1 and E2 
analysis. 
 
1.6.2.1 Potential Risks 
Potential risks for data collection are described in the parent study including those related to 
transcranial Doppler studies, CSF and blood collection and confidentiality (Appendix B). For 
this analysis privacy and confidentiality were assured by not providing individual identifiers.  
 
1.6.3 Recruitment and Informed Consent 
Potential patients for the parent study were identified by physician or nursing staff involved in 
the care of the patient and permission was established for the study team to approach the patient 
and/or family. Procedures, risks and benefits were explained to the patient and/or family and 
consent was obtained. Both surrogate and proxy consent (using Pennsylvania state law 
guidelines) were used due to the cognitive condition of many acute aSAH patients. When 
possible, assent or patient consent was obtained; if not, consent for continued participation was 
obtained when the patient was able to understand and provide consent. Informed consent was 
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obtained from the patient or proxy prior to data collection. The consent allows use of samples for 
future analysis in studies performed by the research team (Appendix C). 
 
1.6.4 Protection Against Risks 
Since this study is a secondary analysis of data and banked samples, there were no acute risks 
associated with collection of the samples. Protections against risks for data collection are 
described in the parent study including confidentiality, use of transcranial Doppler gel and the 
risk of infection and discomfort from sample collection. There was the possibility of a breach of 
confidential patient information, although measures to avoid this were followed. All records 
were kept in locked cabinets within the departments of the principal investigators of the parent 
study.  All specimens were kept in locked freezers at the University of Pittsburgh, under the 
control of the principle investigator of the parent study and accessible only by the research staff.  
A case number is linked to the records and specimens without indicating the subject’s individual 
identity. All analysis was done on coded samples identified in the records only by case number. 
The plasma and CSF samples collected for the parent study are maintained in a –80oC freezer 
utilizing the case numbers.  No results were provided directly to any participant. 
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1.6.5 Potential Benefits of the Proposed Research to the Subjects and Others 
There were no direct benefits to subjects who were included in the study. The general benefit of 
this study was for future patients with aSAH by developing earlier predictors of acute 
complications following aSAH which may result in earlier therapeutic treatments. 
 
1.6.6 Importance of Knowledge Gained from the Proposed Study 
Data from the proposed study, which had not been explored in aSAH, will advance the state of 
the science for patients with hemorrhagic stroke and cerebral insult by addressing a gap in the 
knowledge related to the role of E2 in influencing complications such as DCI which can 
markedly impact patient outcomes. Ultimately advancement of our understanding of the 
mechanisms underlying the development of DCI may result in target therapies and more accurate 
identification of patients at high risk for poor outcomes. 
 
1.6.7 Data Safety Monitoring Plan 
The principal investigator of the parent study is responsible for the maintenance and protection 
of the grant data. The original consent and screening forms are stored in a locked cabinet, 
separate from data storage. All data is entered and maintained in an SPSS database (v. 19.0).  
Paper copies of subject data are labeled with only a unique study identifier for each subject and 
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kept in a locked cabinet. All electronic data is kept on a password-protected computer. Patient 
specimens are maintained in locked study freezers at the University of Pittsburgh School of 
Nursing and labeled only with unique study identifier for each subject. Data and safety 
monitoring related to this secondary analysis were conducted during meetings with the 
dissertation committee. Any adverse events would have been reported immediately to the IRB 
however there were no adverse events. 
 
1.6.8 Inclusion of Women, Minorities and Children 
The racial, gender and ethnic characteristics of the proposed subject population reflects the 
demographics of Pittsburgh and the surrounding area and/or the patient population of the 
University of Pittsburgh Medical Center.  Patient data were not excluded based on race, 
ethnicity, gender or HIV status. The racial characteristics of the parent study include 88% white, 
11% African American and 1% other minority subjects. Research suggests that the majority of 
persons who develop aSAH are female. In the parent study, 75% of the sample is female. For the 
purpose of this study distinct criteria were used to include equal representation of pre and post - 
menopausal females as well as males.  There were no children involved in this study. There were 
no advertisements for this study. 
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2.0  SUMMARY OF STUDY 
The purpose of this study was to examine the association between levels of estrogen (estradiol 
and estrone) and the development of DCI in patients with aSAH. An article describing plasma 
result prepared in the format for submission to Stroke (Aim 1 and 3) is appended to this chapter. 
A second article published in Stroke that describes the relationship between 20-HETE and DCI 
after aSAH is included in bibliography (Crago et al., 2011).  
2.1 FINDINGS RELATED TO AIM 1 
Aim 1. Examine patterns in plasma E1 and E2 levels during the 10 days following aSAH.   
The study variables for analysis were plasma E1 and E2 levels, patient characteristics [age, race, 
gender, menopausal status and severity of injury (HH and fisher scores)] and ischemic outcomes 
including DCI, vasospasm and cerebral ischemia. Binary variables were created for HH and race 
to capture relationships. Both E1 and E2 data were non-normally distributed; therefore data 
transformation (natural logarithmic) was applied. Since few metabolite measurements were not 
quantifiable or below limits of detection [E1-1 sample (<1%), E2-12 samples (4%)], these 
measurements were assigned a number at the limit of detection. Findings related to aim 1 a re 
presented in the manuscript. 
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The sample consisted of 99 aSAH subjects of which 28 were pre-menopausal females, 34 
were post-menopausal females and 37 w ere men.(Table 3) Subjects in this analysis were also 
predominately Caucasian (87%, n=86) with a mean age of 50.03 years (SD=10.1). Severity of 
injury by Hunt and Hess ranged from 1-5 with 46% (n=45) graded as HH 3, while the average 
fisher score was 3 (n=45, 46%) (Table 3). Three plasma samples were selected for E1 and E2 
analysis from each patient representing early (first – 4 days after hemorrhage), middle (4-6 days 
after hemorrhage) and late (7-10 days) after hemorrhage and were analyzed at the SMBC (small 
molecule biomarker core) lab at the University of Pittsburgh School of Pharmacy.  E1 and E2 
measurements were arranged by day (1-10) and values were log transformed for analysis. Group 
based trajectory analysis (SAS v9.2) was used to identify distinct populations over time for both 
E1 and E2 values using censored normal model. Preliminary analyses were conducted to test 
models from one to 4 trajectory groups. The numbers of groups for each hormone were 
determined by evaluating the mixed fit statistics including Entropy, BIC, and AIC. Weighted and 
non-weighted chi-square test and/or Fisher exact test were used to explore the association 
between demographic and outcome variables and the different trajectory classes for both plasma 
E1 and E2 in the first 10 days after SAH. 
There was an estimated 61.4% (n=61) of patients in the E1 high and 38.6% (n=38) in the 
E1 low trajectories with a declining pattern that was significant for both groups (p<.001; mean 
low = 3.9, SD=.69; mean high= 5.12, SD=.66) (Figure 3).  Weighted Chi square analysis 
revealed that compared with patients in the low E1 group, patients in the high E1 group were 
significantly more likely to be female (p=.02), post-menopause (.05), older (p<.001) and had a 
higher severity of injury as evidenced by Fisher grade (p=.008). Although it did not reach 
statistical significance, patients with the presence of DCI were statistically more likely to be in 
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the high E1 group (p=.09), however patients with DCI specifically from infarction, neurological 
decline associated with new CT evidence of cerebral infarction, were more likely to be in the 
high E1 trajectory group (p=.03) (Table 4). 
An estimated 48% (n=46) of the patients were categorized in the E2 high group and 52% 
(n=53) in the E2 low trajectories with both groups displaying a declining pattern (p=.01) (Figure 
4). Using weighted Chi square analysis patients in the high E2 trajectory group were 
significantly younger than those in the low group (p=.02) and were more likely to have higher 
Fisher grade although this was not statistically significant (p=.09). No differences were noted 
between E2 groups by gender, race, menopausal status or HH, and no differences were identified 
by E2 trajectory group and DCI (Table 4). 
These findings support a relationship between severity of injury and estrogen metabolite 
measurements. Patients in the high E1 and E2 trajectory group were more likely to have a higher 
severity of injury by fisher score. E1 levels were also significantly different by age, gender and 
menopausal status with younger and premenopausal women more likely to be in the high 
trajectory group. E2 levels were also significantly different by age; however patients with high 
E2 trajectories were younger than patients in the low E2 trajectory group. Finally, patients who 
developed DCI were more likely to be in the high E1 trajectory group. 
2.2 FINDINGS RELATED TO AIM 2 
Aim 2. Determine the relationship between plasmaE1 and E2 levels and the presence or absence 
of DCI during the 10 days following aSAH. 
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The study variables for aim 2 were plasma E1 and E2 levels, patient characteristics (age, race, 
gender, menopausal status and severity of injury including HH and fisher scores) and DCI 
including individual measurements of blood flow such as cerebral vasospasm, ischemia or 
infarct. Similar to aim one, binary variables were created for HH and race to capture 
relationships. Both E1 and E2 data were non-normally distributed; therefore data transformation 
(natural logarithmic) was applied. As in aim 1, since few metabolite measurements were not 
quantifiable or below limits of detection [E1-1 sample (<1%), E2-12 samples (4%)], these 
measurements were assigned a number at the limit of detection. Findings related to aim 2 a re 
reported in the manuscript. 
This sample also consisted of 99 aSAH subjects with plasma samples as described in aim 
one (Table 3). Using log transformed E1 and E2 measurements multiple logistic regression 
models (GENMOD, SAS v9.2) were conducted to evaluate the relationship between E1 and E2 
measurement and DCI while controlling for possible covariates such as demographic 
characteristics (age, gender, menopausal status and severity of hemorrhage).  
Pre-menopausal aSAH patients had higher mean E1 and E2 levels than both post-
menopausal females and males however this was not statistically significant. Metabolite 
measurements were comparable to other studies using HPLC measurements of E1 and E2 in 
human subjects (Haring et al., 2011; Masi et al., 2009; Naessen et al., 2010; Rothman et al., 
2011; Xu et al., 2007). There was a significant association between plasma E1 and E2 (P<.001).  
Females had higher E1 concentrations than males (p=.06) and E1 levels were statistically 
different by age (p<.001), however this was not found for E2 (p=.31)  (Table 5). 
Higher values of plasma E1 and E2 were associated with higher severity of injury 
regardless of age. Patients with higher HH and Fisher were more likely to have higher plasma E1 
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levels in all analysis except between the groups of HH4 and HH5. Similarly, patients with higher 
HH and Fisher scores were more likely to have higher plasma E2 levels although this was only 
statistically significant between HH groups (1&2 vs 3-5) and Fisher 3 vs Fisher 4 (Table 5). 
The presence of DCI was significantly associated with higher levels of both plasma E1 
(p=.004) and E2 (.03). This relationship to DCI remained significant when severity of injury was 
added to the regression model for both E1 (p=.02) and E2 (p=.08). There was also a significant 
association between DCI from cerebral infarction and both plasma E1 (p<.001) or E2 (p=.05) 
(Table 5). 
Using all variables with a maximum significance of p<.10 from the univariate analyses, 
generalized estimating equation (GEE) models were created to predict E1 and E2. Log plasma 
E1 was significantly associated with DCI (p=.02) and age (p<.001) when controlling for age, 
gender, HH and DCI. In a model with age, gender, Fisher and DCI, age (p<.001), Fisher (p=.05) 
and DCI (p=.003) were significantly associated to E1 levels. Similarly, (log) E2 was analyzed in 
a model of age, HH and DCI with DCI (p=.05) and age (p=.08) having an association to E2 
levels. Using Fisher instead of HH in the model, DCI was significantly associated with E2 levels 
(p=.02).  
These findings are consistent with the findings related to study Aim 1 w hich support a 
relationship between plasma E1 and E2 measurements and severity of injury. Further, a 
significant relationship was identified between higher levels of E1 and E2 and the presence of 
DCI after aSAH while controlling for severity of injury.  
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2.3 FINDINGS RELATED TO AIM 3 
Aim 3. Examine patterns in CSF E1 and E2 levels during the 10 days following aSAH. 
The study variables for analysis were CSF E1 and E2 levels, patient characteristics [age, race, 
gender, menopausal status and severity of injury (HH and fisher scores)] and ischemic outcomes 
including DCI, vasospasm and cerebral ischemia. Binary variables were created for HH and race 
to capture relationships. Both E1 and E2 CSF data were non-normally distributed, therefore data 
transformation (natural logarithmic) were applied. 
The sample consisted of 36 a SAH subjects with CSF samples of which 11 w ere 
premenopausal females, 11 were post-menopausal females and 14 were men (Table 6). Subjects 
in this analysis were also predominately Caucasian (78%, n=28) with a mean age of 49.9 years 
(Table 6).  Severity of injury by Hunt and Hess ranged from 1-5 with 44% graded as HH 3, while 
the average fisher grade was 3 (47%) (Table 6).  Up to 5 CSF samples were selected for E1 and 
E2 analysis from each patient representing the first available sample, a sample from the 10th day 
after hemorrhage and 1-3 samples in between.  S amples were analyzed at the SMBC at the 
University of Pittsburgh School of Pharmacy.  E 2 levels were only detected in 33% of the 
samples analyzed which was consistent across gender and menopausal status. E1 levels were 
more consistently measured and were detected in 83% of samples that were analyzed. E1 and E2 
measurements were arranged by day (1-10) and values were log transformed for analysis. Group 
based trajectory analysis (SAS v9.2) was used to identify distinct populations over time for both 
E1 and E2 values using censored normal model. Preliminary analyses were conducted to test 
models from one to 4 trajectory groups. The number of groups for each hormone was determined 
by evaluating the mixed fit statistics including Entropy, BIC, and AIC. Weighted and non-
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weighted chi-square test and/or Fisher exact test were used to explore the association between 
demographic and outcome variables and the different trajectory classes for both CSF E1 and E2 
in the first 10 days after SAH.  
There was an estimated 58% (n=22) of patients in the E1 low and 42% (n=14) in the E1 
high trajectories with a constant pattern over time in the high group and a significantly declining 
pattern in the E1 low group (p=.04) (Figure 5). Using non weighted chi square, significant 
differences were noted between groups by HH (p=.03) and DCI (p=.06) and specifically DCI 
from vasospasm (p=.02) (Table 7). The relationship between group and DCI did not remain 
significant using weighted chi squares (p=.12) (Table 7). Patients with higher HH score, DCI and 
specifically DCI from vasospasm were more likely to be in the consistently high CSF E1 group. 
Mixed fit statistics were improved using a 3 group trajectory for E1 measurements. There were 
an estimated 61.3% of patients in the E1 low group, 22.4% in the E1 higher group and an 
estimated 16.3% in a third E1 group which declined over time (Figure 6).  Using weighted and 
non-weighted chi-square test and/or Fisher exact test to explore the association between 
demographic and outcome variables higher HH was associated with the high E1 group in the 2 
group trajectory model (p=.04). In the 3 trajectory classes only gender (p=.009) was significantly 
associated with group membership. In the 3 group analysis, only male patients were found in the 
third E1 group which declined over time (Table 7). No relationship was identified between E1 
trajectory groups and DCI. 
Trajectory analysis for E2 CSF levels resulted in relatively poor fit statistics in all 
attempted models which may be a result of both sample volume and low detectable levels in the 
samples that were quantified. In the best trajectory model resulting in 2 linear groups, there was 
an estimated 41% (n=10) of patients in the E2 CSF low and 58% (n=26) in the E2 CSF high 
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trajectories. In this model the high trajectory significantly declined over time (p=.05) while the 
low trajectory had a consistent pattern over time (Figure 7).  Using weighted Chi Square analysis 
no statistical differences were identified between groups (Table 7). 
These findings provide evidence that estrogen metabolites are measureable in CSF and 
that a relationship exists between severity of injury and estrogen metabolites in CSF. Patients in 
the high E1 trajectory group were more likely to have a higher severity of injury by HH score 
and to develop DCI.  
 
2.4 FINDINGS RELATED TO AIM 4 
Aim 4. Determine the relationship between CSF E1 and E2 levels and the presence or absence 
of DCI during the 10 days following aSAH. 
The study variables for Aim 4 were CSF E1 and E2 levels, patient characteristics [age, race, 
gender, menopausal status and severity of injury (HH and fisher scores)] and ischemic outcomes 
including DCI, vasospasm and cerebral ischemia. Binary variables were created for HH and race 
to capture relationships. Both E1 and E2 CSF data were non-normally distributed, therefore data 
transformation (natural logarithmic) were applied.  
As in aim 3, the sample consisted of 36 aSAH subjects with CSF samples (Table 6).  Up 
to 5 CSF samples were selected for E1 and E2 analysis from each patient representing the first 
available sample, a sample from the 10th day after hemorrhage and 1-3 samples in between.  
Samples were analyzed at the SMBC lab at the University of Pittsburgh School of Pharmacy.  E2 
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levels were only detected in 33% of the samples analyzed which was consistent across gender 
and menopausal status. E1 levels were more consistently measured and were detected in 83% of 
samples that were analyzed. Using log transformed E1 and E2 measurements logistic regression 
models (PROC MIXED, SAS v9.2) were conducted to evaluate the relationship between E1 and 
E2 CSF measurement and DCI while controlling for possible covariates including such as 
demographic characteristics (age, gender, menopausal status and severity of hemorrhage). In 
addition, because of the level of detection of E2 in CSF, estrogen metabolites were dichotomized 
into groups of detectable and non-detectable concentrations.  Chi-square test and/or Fisher exact 
test were conducted to explore the association between detectable and non-detectable levels of 
E1 and E2 in CSF with socio-demographic, clinical, and DCI factors.  
There was a significant relationship between CSF E1 and E2 concentrations (p<.001). 
Although limited references exist, metabolite levels were comparable to other studies using 
HPLC measurements of CSF E1 and E2 in human subjects (Nguyen et al., 2011).  Using log 
metabolite levels, higher CSF E1 measurements were associated with higher HH scores (p=.03) 
(Table 8). Similarly higher fisher scores were associated with higher CSF E1 concentrations, 
where patients graded Fisher 2 had lower concentrations of CSF E1 than patients with Fisher 4 
grade (p=.06).  Higher CSF E1 levels were also associated with DCI from vasospasm (p=.05) 
however relationships were not identified in other ischemic outcomes including DCI (p=.24). 
There were no difference noted between CSF E2 and severity of injury or DCI (Table 8).  There 
were no identified differences between groups of detectable versus non-detectable concentrations 
in either CSF E1 or CSF E2 (Table 8). 
Consistencies in study findings were identified between estrogen metabolites in CSF and 
plasma where higher levels of CSF E1 were associated with severity of injury after aSAH. 
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However, these findings need for additional patients and sample selection to effectively explore 
this aim.  
2.5 FINDINGS RELATED TO AIM 5 
Aim 5. Explore the associations among CSF levels of E1 and E2, 20-HETE and EET and the 
presence or absence of DCI following aSAH.  
This exploratory aim used the study variables CSF E1, E2, 20HETE, 11,12 DHET and 14,15 
DHET and DCI. All of the CSF measurement data were non-normally distributed; therefore data 
transformation (natural logarithmic) was applied. Any metabolite measurements below limits of 
detection were excluded from the analysis. 
As in aim 3 and 4, the sample consisted of 36 aSAH subjects with CSF samples (Table 
4).  Up to 5 CSF samples were selected for E1 and E2 analysis from each patient representing the 
first available sample, a sample from the 10th day after hemorrhage and 1-3 samples in between.  
In addition CSF 20HETE, 11,12 DiHET and 14,15 DiHET measurements at the same time points 
were entered into the database. All samples were analyzed at the CORE lab at the University of 
Pittsburgh School of Pharmacy.  As described in aim 3, E2 levels were only detected in 33% of 
samples analyzed while E1 levels were more consistently measured and were detected in 83% of 
samples that were analyzed. CSF 20HETE was quantified in 122 samples (76%), while 11,12 
DiHET was measured in 53% (n=86) and 14,15 DiHET in 66% (n=107). Using log transformed 
measurements of all CSF metabolites regression models (PROC MIXED, SAS v9.2) were 
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conducted to evaluate the relationship between levels of E1 and E2 with 20HETE, 11,12 DiHET 
and 14,15 DiHET measurements in CSF as well as DCI. 
No relationships were identified between CSF E2 and 20HETE (p=.85), 11,12 DiHET 
(p=.3) or 14,15 DiHET (p=.63). A significant relationship was noted between CSF E1 and 20-
HETE (p=.05). And although not significant, a relationship was noted between 11,12 DiHET 
(p=.07) and CSF E1. No relationship was found between CSF E1 and 14,15 DiHET (p=.21). The 
relationship between CSF E1 and DCI did not reach significance in models containing CSF 20-
HETE and CSF 11,12 DiHET. A low percentage of HETE and DiHET detection in this already 
small sample size is a limiting factor in this analysis, however there are indications that 
relationships exist between these vasoactive metabolites warranting the need for additional 
patients and sample selection to effectively answer this aim.   
 
2.6 RECOMMENDATIONS AND LIMITATIONS 
This study only analyzed E1 and E2 levels after aSAH. Future studies should include other 
neurosteroid levels (progesterone, allopreganalone and testosterone) as well as growth hormone 
(IGF-1) and inflammatory markers (cortisol, interleukins or CRP) to provide additional 
information and explanation of findings. At the same time, measurement of FSH and LH could 
enhance the evaluation of menstrual cycle and menopause in females as well as provide 
documentation for hormone suppression. A second limitation is that the population of aSAH 
patients selected for this study was based on availability of cerebral spinal fluid. Patients who 
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require placement of external ventricular catheters represent a subgroup of aSAH patients who 
have higher severity grades and may have higher risk of complications after aSAH due to extent 
of injury including DCI.  M easuring plasma estrogen concentrations on all aSAH patients 
regardless of CSF availability would capture a larger sample volume and would further evaluate 
the association between estrogen measurements and severity of injury since patients with less 
symptom burden and blood load are less likely to have CSF drainage devices. 
A third limitation is the definition of DCI. In this analysis we defined DCI via 
components of altered blood flow in the presence of neurological deterioration. Although the 
definition is similar to the most recently defined criteria for DCI it does use TCD information in 
addition to cerebral blood flow and CT information.  Not all patients in this analysis had 
angiographic data available, as it is performed as a result of clinical changes rather than research 
protocols; therefore the correlation with angiographic vasospasm is on a subset of this patient 
sample. Furthermore determining a clinical change on a patient with poor neurological condition 
from the onset of injury limits the use of neurological assessment used to determine whether the 
patient has symptomatic ischemia.  
While there were 99 patients in the plasma analysis portion of this study only a subset 
(n=36) of patients with CSF were analyzed. Future studies should consider more subjects as well 
as more data time points. Additional samples would provide more robust trajectory analysis and 
with additional sample time points, estrogen levels could be analyzed by time to ischemic 
complications using survival analysis and CSF findings. It would also allow the addition of 
analytical models to explore changes in multiple metabolites measurements after aSAH in 
relationship to ischemic outcomes. Using more complex modeling techniques may help to 
promote understanding of hormone relationships to injury as well as outcomes. In the meantime, 
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correlations between CSF and plasma levels should be evaluated. Other considerations include 
survival analysis to evaluate if E1 and/or E2 concentrations are related to the time of DCI.  
Further, metabolite concentrations could be analyzed using ROC curves to potentially determine 
a threshold when E1 and/or E2 concentrations are predictive of ischemic outcomes after aSAH.   
Future studies should also analyze acute and long term outcomes including mortality, 
functional disabilities and neuropsychological outcomes to determine if higher estrogen levels 
also correspond with more long term consequences.  F inally, the exploration of estrogen 
receptors ERα and ERβ should be completed since availability of these receptors has been linked 
to the presence and the influence of estrogen in the central nervous system. 
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3.0  RESULTS MANUSCRIPT #1 
3.1 ABSTRACT 
Background and Purpose:  Delayed cerebral ischemia (DCI) causes significant morbidity and 
mortality following aneurysmal subarachnoid hemorrhage (aSAH). Although the precise 
mechanisms are not known, recent evidence has suggested that biochemical mediators alter 
cerebral perfusion and are a p rimary mechanism for neurological decline. Estrogens (estrone – 
E1 and estradiol – E2) are mediators that have demonstrated neuroprotective properties that 
could play a role in DCI. There is a dearth of literature evaluating the impact of E1 or E2 on 
outcomes in humans following aSAH. The purpose of this study is to examine the association 
between E1 and E2 levels and DCI following aSAH. 
Methods:  Plasma samples were collected after hemorrhage on 99 acute, adult aSAH 
patients admitted to the Neurovascular ICU enrolled in a NIH funded study (RO1NR004339).  
Three plasma samples were selected for E1 and E2 analysis from each patient representing early 
(1–4), middle (4-6) and late (7-10) days after hemorrhage and were assayed using liquid 
chromatography-tandem mass spectrometry. DCI was operationalized as radiographic/ultrasonic 
evidence of impaired cerebral blood flow accompanied by neurological deterioration. Statistical 
analysis included detailed descriptive, group based trajectory and multiple logistic regression 
using SAS v9.2. 
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Results and Conclusions:  Group based trajectory identified 2 d istinct populations over 
time for both E1 (61.4% E1 high and 38.6% E1 low) and E2 (48% E2 high and 52% E2 low) 
values using censored normal model. Weighted Chi Square analysis identified differences 
between trajectory groups by gender (p=.02), menopause (.05), age (p<.001) and fisher grade 
(p=.008) with patients in the high E1 group having higher severity of injury than those in the low 
E1group.  Likewise, patients with higher HH (E1 p=.01, E2 p=.02) and Fisher (E1 p=.008, E2 p= 
.08) were more likely to have higher plasma estrogen levels. The presence of DCI was also 
significantly associated with higher levels of plasma E1 (p=.002) and E2 (.03) as well as the high 
E1 trajectory group (p=.09). These results provide the first clinical evidence that E1 and E2 
concentrations are associated with severity of injury and DCI and provide incentive for future 
studies to clarify the potential role of estrogen in ischemic complications of patients with aSAH. 
3.2 INTRODUCTION 
Aneurysmal subarachnoid hemorrhage (aSAH) is a sudden and devastating neurological event 
affecting approximately 10 in 100,000 persons annually and resulting in significant morbidity 
and mortality (Cahill & Zhang, 2009).  Despite advances in medical and surgical management, 
aSAH continues to be associated with complications which necessitate vigilant monitoring and 
emergent interventions during the acute recovery period (Cahill & Zhang, 2009; Frontera et al., 
2009; Ostrowski, et al., 2006; Sehba et al., 2011; Zubkov & Rabinstein, 2009). Following 
hospital discharge, many patients experience long-term functional and cognitive impairment that 
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impacts their ability to resume previously held familial, social and occupational roles 
(Vergouwen et al., 2009). 
Unstable intracranial physiology and systemic medical complications are common after 
aSAH and have a direct impact on outcomes (Rose, 2011).  Cerebral edema and hemorrhage may 
occur but do not adequately predict the risk of neurological decline and poor outcomes after 
aSAH (Cahill & Zhang, 2009; Frontera et al., 2009)   Similarly, cerebral vasospasm that causes 
vessel narrowing can result in regional reduction of cerebral perfusion and has been a primary 
focus of research and treatment after aSAH (Cahill & Zhang, 2009; Frontera et al., 2009; 
Keyroux & Diringer, 2007; Ostrowski, et al., 2006; Rose, 2011; Sehba et al., 2011; Vergouwen 
et al., 2009; Zubkov & Rabinstein, 2009).  The diagnosis of cerebral vasospasm is often based on 
visualization of the macrovascular circulation using cerebral angiography which has been 
inconsistently associated with neurologic decline complications and/or long term outcomes 
(Cahill & Zhang, 2009; Frontera et al., 2009; Ostrowski, et al., 2006; Sehba et al., 2011; 
Vergouwen et al., 2009; Zubkov & Rabinstein, 2009).  
More recently, delayed cerebral ischemia (DCI) has been implicated as a leading cause of 
poor outcomes following aSAH (Vergouwen et al., 2009).   DCI, which occurs in approximately 
20-60% of patients who survive the initial hemorrhage (Cahill & Zhang, 2009; Frontera et al., 
2009; Keyroux & Diringer, 2007; Ostrowski, et al., 2006; Rose, 2011; Sehba et al., 2011; 
Vergouwen et al., 2009; Zubkov & Rabinstein, 2009),  is thought to be the result of a mismatch 
between available cerebral blood flow (CBF) and metabolic demands of  brain tissue, a 
consequence that leads to neuronal changes and neurological decline (Crago et al., 2011; Dupont 
et al., 2009;  Kolias et al., 2009; Macdonald et al., 2008; Vergouwen et al., 2011a).  In order to 
provide early intervention and potentially reverse ischemia, it is important to promptly recognize 
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and treat DCI.  H owever, clear clinical indicators of DCI have not been identified. While 
associations between vasospasm, cerebral infarction, DCI, and poor outcomes have been 
reported, each may occur independently.  O f concern, reduced incidence of angiographic 
vasospasm has not significantly altered the development of ischemic complications or improved 
outcomes (Cahill & Zhang, 2009; Crago et al., 2011; Dupont et al., 2009; Frontera et al., 2009; 
Kolias et al., 2009; Macdonald et al., 2008; Ostrowski, et al., 2006; Sehba et al., 2011; 
Vergouwen et al., 2011a; Vergouwen et al., 2009; Zubkov & Rabinstein, 2009).  
More recently, microvascular dysfunction or changes are theorized to be involved in the 
pathogenesis of DCI (Vergouwen et al., 2009). The origin of these microvascular alterations may 
result from molecular and cellular changes that alter vascular dynamics and cerebral perfusion. 
Therefore shifts in vasoactive metabolite levels could provide markers of ischemic complications 
after neurologic insults (Ostrowski et al., 2006; Sehba et al., 2011; Crago et al., 2011; Dupont et 
al., 2009;  Losniecki & Zuccarello, 2008; Macdonald et al., 2008).   Estrogen has been widely 
studied in neurological disorders including both experimental ischemic and hemorrhagic insults 
(Azcoitia et al., 2011; Carwile et al., 2009; Herson et al., 2009).  
Estradiol (E2) alters vascular reactivity, reduces tissue damage, improves functional 
recovery and may stimulate repair processes in the CNS (Herson et al., 2009). The absence of E2 
has been linked to vasoconstriction, impaired cellular metabolism and cellular death in animal 
models (Brown et al., 2009; Herson et al., 2009).  In humans, increased levels of E2 have been 
positively correlated with improved outcomes in stroke and traumatic brain injured patients 
(Azcoitia et al., 2011; Brown et al., 2009; Carwile et al., 2009; Herson et al., 2009; Krause et al., 
2006).  Estrone (E1) is a physiologic estrogen that is the predominant estrogen remaining after 
menopause. In experimental studies E1 has been related to vascular reactivity and vasodilation 
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through nitrous oxide pathways (Gatson et al., 2011; Rauschemberger et al., 2011, Selles et al., 
2005).  It has also demonstrated neuroprotective properties in animal stroke, reperfusion injury 
and TBI studies (Gatson et al., 2011; Rauschemberger et al., 2011, Selles et al., 2005).  More 
recently, higher estrogen levels have been associated with greater severity of injury and illness in 
patients and have been implicated as potential independent markers of poor outcomes in these 
populations (Lerchbaum et al., 2011; Kauffman et al., 2011; Wagner et al., 2011).  No study has 
been found to date that explores whether changes in estrogen levels are related to reduced 
ischemic complications and improved outcomes in patients with aSAH. The purpose of this 
study was to examine patterns in plasma E1 and E2 concentrations and to determine the 
relationship between plasma E1 and E2 concentrations and presence or absence of DCI in the 10 
days following aSAH with the hypothesis that higher estrogen levels would result in lower 
incidence of delayed cerebral ischemia. 
 
3.3 METHODS 
3.3.1 Patient Sample 
This study was a secondary analysis of data from adult patients with acute aSAH admitted to the 
neurovascular intensive care unit at the University of Pittsburgh Medical Center (UPMC) 
Presbyterian Hospital who were enrolled in a NIH-funded study (R01NR004339) exploring the 
relationship between biomarkers and complications of aSAH.  Inclusion criteria for the parent 
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study were: 1) 21-75 years; 2) verified aneurysmal SAH; and 3) Fisher grade > 1 (determined by 
evidence of blood on CT scan) and/or Hunt and Hess (HH) >2. Exclusion criteria were: 1) non 
aneurysmal SAH; 2) mycotic aneurysm or 3) history of preexisting debilitating neurologic 
disease. In addition, eligibility for this analysis included the availability of at least 3 plasma 
samples. The sample was stratified to include women (both pre- and postmenopausal) and men 
without statistical differences in severity of injury or incidence of DCI. Females on oral 
contraceptives or estrogen replacement were excluded from the analysis. The parent study was 
approved by the Institutional Review Board and informed consent was obtained from the patient 
or proxy prior to data collection.  
 
3.3.2 Data Collection 
Socio-demographic data including gender, age, race, severity of injury (Fisher Grade and Hunt & 
Hess (HH) Score) as well as clinical data were collected from the medical record.   
 
3.3.3 Estrogen Measurement 
In order to capture changes in circulating estrogen levels, 3 plasma samples per subject were 
analyzed for E1 and E2 concentrations including the initial (first) sample, a middle sample (day 5 
to 7) and at days 10 after hemorrhage. Samples were collected each morning (8am +/- 1 hour) 
and evening (7pm +/- 1 hour) from consent through 10 days after initial hemorrhage, centrifuged 
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for 5 minutes at 2500rpm and aliquoted into cryovials within 60 minutes of collection. They 
were stored at -80°C until analysis.  
E1 and E2 were assayed at the University of Pittsburgh Small Molecule Biomarker Core, 
using liquid chromatography-tandem mass spectrometry (LC-MS/MS).  T he UPLC-MS/MS 
method employs liquid-liquid extraction, derivatization and detection with a t riple quad mass 
spectrometer.  Plasma is spiked with with n-butyl chloride, derivatized with dansyl chloride and 
transferred to autosampler glass vials for injection. E2 is eluted from a Waters Acquity UPLC 
BEH C18, 1.7 um, 2.1x150 mm reversed-phase column, with an acetonitrile: water (0.1% formic 
acid) gradient. Detection and quantitation are achieved in the positive mode with a Thermo 
Fisher TSQ Quantum Ultra mass spectrometer interfaced via an electrospray ionization (ESI) 
probe with the Waters UPLC Acquity solvent delivery system.  Transitions used for analysis are 
506 --> 171 for estradiol, 504  171 for estrone, and 511 --> 171 for the deuterated internal 
standard. The calibration curves, obtained from extracting known concentrations of E1 and E2 
from 2-hydroxypropyl-beta-cyclodextrin (0.2% in water), range from 0.5 pg/ml (lower limit of 
quantitation) to 200 pg/ ml. The limit of detection is 0.5 pg/ml.  All back calculations of 
calibrators, inter-day and intra-day precision and accuracy, and stability are within acceptable 
limits (<15% at all tested concentrations) (Nelson et al., 2004). 
 
3.3.4 DCI 
DCI was defined as the evidence of impaired CBF accompanied by neurological deterioration 
(simultaneously or within 12 hours pre or post determination of impaired CBF). Neurological 
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deterioration was defined by the presence of any of the following: at least a 2 point increase in 
National Institute of Health Stroke Scale (NIHSS) and or decline in Glasgow coma score (GCS);  
deterioration in pupil reaction; nursing documentation of a focal deficit (visible weakness or 
difficulty speaking); or nursing documentation of a decline in level of consciousness (lethargy, 
agitation, confusion) not associated with fever or medication administration (such as sedatives, 
paralytics or anti-anxiety medications). Cerebral blood flow was assessed by cerebral 
angiography, transcranial Doppler (TCD) and CT or MR perfusion scans. Angiographic 
vasospasm was determined from cerebral angiograms read and coded by neurosurgeons blinded 
to participant identity and dichotomized as either ‘negative’ (0-24% narrowing of cerebral blood 
vessels) or ‘positive’ (>25% narrowing of cerebral blood vessels). Daily TCDs were coded as 
abnormal flows when there was a systolic middle cerebral artery velocity > 200 ml/sec and/or a 
Lindegaard ratio > 3.0. Finally, head CT/MR and head CT/MR perfusion scans were reviewed 
for the presence of ischemia, infarction or low blood flow in the absence of hydrocephalus or 
rebleed by study personnel.  All patients received standard therapy for the study institution for 
SAH patients including strict blood pressure and central venous pressure parameters, nimodipine 
and triple H therapy. 
 
3.3.5 Data Analysis 
Plasma E1 and E2 measurements were analyzed in two ways. Both E1 and E2 data were not 
normally distributed; therefore data transformation (natural logarithmic) was applied. Since few 
metabolite measurements were not quantifiable or below limits of detection [E1-1 sample (<1%), 
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E2-12 samples (4%)], these measurements were assigned a number at the limit of detection First, 
group-based trajectory analysis (Nagin & Odgers, 2010) was used to identify the distinct short-
term patterns (homogeneous latent trajectory classes) of E1 and E2 from day 1 to day 10 after 
initial hemorrhage. Group based trajectory also controls for missing data and inconsistent data 
points. Preliminary analyses were conducted to test models from one to 4 groups.  The number of 
groups for each hormone were then tested and compared based on model selection such as 
statistical significance, entropy, the Bayesian Information Criterion (BIC), and the substantive 
utility of the classes (e.g. distinctiveness of the trajectories, proportion assigned to a given class) 
along with clinical judgment to determine the optimal solution for the number of trajectory 
groups. Using SAS 9.2  weighted and non-weighted chi-square test and/or Fisher exact test were 
used to explore the association between demographic and outcome variables and the different 
trajectory classes for both plasma E1 and E2 in the first 10 days after SAH. 
Second, using log transformed E1 and E2 measurements,  generalized estimating  
equation  models (GENMOD, SAS v9.2) were conducted to evaluate the relationship between 
E1 and E2 measurement and DCI while controlling for possible covariates such as demographic 
characteristics (age, gender, menopausal status and severity of hemorrhage).  
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3.4 RESULTS 
3.4.1 Patient Characteristics 
The sample consisted of 99 aSAH subjects of whom 28 were pre-menopausal females, 34 were 
post-menopausal females and 37 were men (Table 3). Subjects in this analysis were 
predominately Caucasian (87%, n=86) with a mean age of 50.4 years (SD=10.1). Age was not 
stignficantly different between males and females with the exception of pre and postmenopausal 
female groups. Severity of injury by Hunt and Hess ranged from 1-5 with 46% (n=45) graded as 
HH 3, while the average fisher score was 3 (n=45, 46%).   Of the patients with DCI (46%; n=45), 
a combination of vasospasm demonstrated by cerebral angiography and/or TCD along with 
neurological deterioration was present in 38 patients. The presence of new cerebral ischemia or 
infarct along with neurological decline was used in the other 7 patients with DCI. DCI could not 
be determined on 3 patients (3%) due to poor neurological condition which precluded  the ability 
to derive a neurologic deterioration. They were excluded from any analysis involving DCI. 
(Table 3) 
 
3.4.2 Plasma Estrogen Levels Following aSAH 
E1 and E2 measurements were arranged by day (1-10) and values were log transformed for 
analysis. Group based trajectory analysis (SAS v9.2) was used to identify 2 distinct populations 
over time for both E1 and E2 values using censored normal model. There was an estimated 
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61.4% (n=61) patients in the E1 high and 38.6% (n=38) in the E1 low trajectories, with a 
significant declining pattern in both groups (p<.001; mean low = 3.9, SD=.69; mean high= 5.12, 
SD=.66) (Figure 3). Weighted chi square analysis revealed that compared with patients in the 
low E1 group, patients in the high E1 group were significantly more likely to be female (p=.02), 
post-menopausal (.05), older (p<.001) and have a higher severity of injury as evidenced by 
Fisher grade (p=.008).  No differences were noted between groups by race or HH. There was an 
estimated 48% (n=46) patients in the E2 high and 52% (n=53) in the E2 low trajectories with 
both groups displaying a significant declining pattern (p=.01) (Figure 4). Using weighted chi 
square analysis patients in the high E2 trajectory group were significantly younger than those in 
the low group (p=.02) and were more likely to have a higher Fisher grade although not 
statistically significant (p=.09).  No differences were noted between E2 groups by gender, race, 
menopausal status or HH (Table 4). 
Using log transformed E1 and E2 measurements multiple logistic regression models 
(GENMOD, SAS v9.2) were conducted to evaluate the relationship between E1 and E2 and key 
demographic variables. Pre-menopausal aSAH patients had higher mean E1 and E2 levels than 
both post-menopausal females and males however these were not statistically significant (Table 
5). Metabolite measurements were comparable to other studies using HPLC measurements of E1 
and E2 in human subjects (Haring et al., 2011; Masi et al., 2009; Naessen et al., 2010; Rothman 
et al., 2011; Xu et al., 2007). There was a significant association between plasma E1 and E2 
levels (P<.001).  Younger patients had significantly higher levels of E1 (p<.001) but not E2 
(p=.27)  (Table 5). 
Plasma E1 and E2 were associated with severity of injury. Patients with higher HH (HH1, 
HH2 and HH3 versus HH 5) and Fisher were significantly more likely to have higher plasma E1 
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levels.  S imilarly, patients with higher HH and Fisher scores were more likely to have higher 
plasma E2 levels between HH groups (1&2 vs 3-5) and Fisher 3 versus Fisher 4 (Table 5). 
 
3.4.3 Plasma Estrogen Levels and Ischemic Outcomes 
DCI was associated with E1 trajectory groups. Patients in the high E1 group had a trend toward a 
marginally significant relationship with the presence of DCI (p=.09), and patients with DCI 
specifically from infarction were significantly more likely to be in the high E1 trajectory group 
(p=.03). No differences were noted between groups by individual blood flow measurements such 
as vasospasm, ischemia or infarction (Table 3). No differences were noted between E2 trajectory 
groups and DCI or individual blood flow measurements (Table 4). 
Using log transformed E1 and E2 measurements multiple logistic regression models 
(GENMOD, SAS v9.2) were conducted to evaluate the relationship between E1 and E2 and 
ischemic outcomes. The presence of DCI was significantly associated with higher levels of both 
plasma E1 (p=.002) and E2 (.03). Patients with DCI had a mean E1=140.4pg/ml (SD=145.2) and 
mean E2 = 8.7pg/ml (SD 19.3) when compared to patients without DCI with a mean E1 = 91.2 
pg/ml (SD=89.5) and mean E2 = 12.9 pg/ml (SD 13.5). There was also a significant association 
between DCI from cerebral infarction and both plasma E1 (p<.001) and E2 (p=.05).  There was 
no significant interaction effect between HH and DCI or age and DCI.  N o associations were 
identified between estrogen levels and individual measurements of cerebral blood flow including 
vasospasm, ischemia, infarction or stroke (Table 5). 
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Using all variables with a maximum significance of p=.10 from the univariate analyses, 
generalized estimating equation (GEE) models were created to predict E1 and E2. Log plasma 
E1 was significantly associated with DCI (p=.02) and age (p<.001) when controlling for age, 
gender, HH and DCI. In a model with age, gender, Fisher and DCI, age (p<.001), Fisher (p=.05) 
and DCI (p=.003) were significantly associated with E1levels. Similarly, (log) E2 was analyzed 
in a model of age, HH and DCI with DCI (p=.05) and age (p=.08) having an association with E2 
levels. Using Fisher instead of HH in the model, DCI was significantly associated with E2 levels 
(p=.02).  
 
3.5 DISCUSSION 
This is the first known clinical evidence of plasma E1 and E2 concentrations in a large cohort of 
aSAH patients. In this study plasma estrogen levels were associated with severity of injury and 
DCI after aSAH. Using trajectory analysis, patterns were noted between higher levels of E1and 
higher Fisher scores. Using regression analysis, both higher E1 and E2 concentrations were 
significantly associated with higher HH and Fisher scores.  H igher estrogen levels were also 
associated with delayed cerebral ischemia. Higher E1 trajectory groups and well as higher E1 
and E2 levels were significantly associated with this ischemic complication. 
The correlation between higher levels of estrogen and greater severity of injury are 
consistent with the most current literature related to estrogens and critical illness in humans. 
High estrogen levels, primarily E2, have been associated with greater severity of injury and poor 
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outcomes after traumatic brain injury (May et al., 2008; Wagner et al., 2011); sepsis, critical 
illness and post op coronary artery bypass patients (Lerchbaum et al., 2011; Kauffman et al., 
2011; May et al., 2008).  Increased hormone levels were also noted independent of age or gender 
(May et al., 2008).  In many cases, higher estrogen levels were associated with higher markers of 
stress response such as cortisol, interleukins and c-reactive protein (Kauffman et al., 2011; May 
et al., 2008; Spratt et al., 2006; Wagner et al., 2011).  In these settings, stimulation of 
inflammatory cytokines has been a co ntributing factor to increased estrogen levels through 
increased peripheral aromatization (Kauffman et al., 2011; May et al., 2008; Spratt et al., 2006; 
Wagner et al., 2011).  Following aSAH, inflammatory mediators released in response to 
aneurysm rupture and the coinciding blood in the arachnoid space (Sehba et al., 2012; Frontera et 
al., 2012) could result in a subsequent increase in hormone production. Estrogen may be a 
protective response to a more severe injury which may be the reason that E1 and E2 levels are 
associated with a common pathologic mechanism such as inflammation that is also indicative of 
worse injury further compounding the elevation of E1 and E2 levels. 
Animal literature has provided considerable support that estrogen possesses 
neuroprotective properties. In pre-clinical studies, increased estrogen levels have been associated 
with decreased ischemia and infarct after hemorrhagic, traumatic and ischemic neurological 
insults (Alkayed et al., 1998; Auriat et al., 2005; Lin et al., 2009; Shih et al., 2008; Sribnick et 
al., 2009 Yang et al., 2001).  For this analysis, we hypothesized that increased serum estrogens 
after aSAH would result in lower incidence of delayed cerebral ischemia; however increase in 
serum estrogens did not translate into neuroprotection from delayed ischemic events. Other 
factors necessary for estrogen supported neuroprotection warrant explanation to investigate and 
substantiate these findings.   
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The means by which estrogen may provide neurological protection may be dependent on 
other factors which could be altered by neurological insult.  Neuronal injuries that might impact 
other brain structures, specifically the pituitary and hypothalamus, could mitigate estradiol 
neuroprotection. Insulin growth factor (IGF-1) has been has been reported to attenuate the 
neuroprotective actions of estrogen (Azcoitia et al., 2011; Selvamani & Sohrabji, 2010).  Aging 
and estrogen reduces the levels of circulating IGF-1 in young and middle-aged females, which 
along with an age-related decline in IGF-1 may be harmful for the injured brain. Stroke severity 
in older females has been associated with decreased IGF-1, while treatment with IGF-1 resulted 
in reduced infarct size and the development of compensatory post-stroke cellular events in an 
animal model (Azcoitia et al., 2011).  Low IGF-1 has also been associated with increased 
morbidity and mortality in ischemic heart disease and stroke (Selvamani & Sohrabji, 2010).  In a 
study of aSAH patients (n=30) IGF-1 concentrations were low following ictus and returned to 
baseline at 3 months (Bendel et al., 2010).  
Estrogen receptors (ERs) are necessary for estradiol actions.  ERα and ERβ, necessary for 
the inflammatory and neuroprotective responses, may be suppressed in such a manner that these 
mechanisms are diminished. ERα has been implicated in anti-inflammatory and protective 
mechanisms while ERβ may be more active in recovery after insult. Selective estrogen receptor 
modulators (SERMs) have been shown to reduce brain inflammation, neurodegeneration and 
promote positive cognitive outcomes in animal studies (Kipp et al., 2011; Yi et al., 2011). 
Increased estrogen levels may be associated with enhanced clotting mechanisms that 
could lead to small vessel ischemia after aSAH. Animal studies suggest that major coagulation 
and inflammation disorders occur early after SAH and may contribute to cerebral ischemia and 
early brain injury (Kasius et al., 2010).  Frontera reported that markers of platelet activation and 
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inflammation were consistently and significantly elevated in severely injured patients after 
aneurysm rupture and prior to cerebral vasospasm (Frontera et al., 2012).  
There has been speculation that differences between human and animal models may 
provide some explanation for the divergence of results. First, animal studies use isolated 
neurological insult which does not result in the robust inflammatory response that occurs after 
critical insults (Kauffman et al., 2011; May et al., 2008; Spratt et al., 2006; Wagner et al., 2011). 
Second, peripheral estrogen aromatization activated by the stress response may occur to a greater 
extent in primates and humans versus rodent species (Simpson, 2004).  S ince the majority of 
preclinical studies have been done in rodent models, applicability of some animal findings to 
clinical outcomes in patients has been questioned (Kauffman et al., 2011; May et al., 2008; 
Spratt et al., 2006; Wagner et al., 2011). 
The balance between estrogens and other neurosteroids such as progesterones and 
allopreganalone may play a role in ischemic outcomes (Azcoitia et al., 2011).  Rapid changes in 
estrogens have been reported in other neurovascular events such as central venous thrombosis. 
Progesterone has become a target for clinical trials in traumatic brain injured patients (Espinoza 
& Wright, 2011).  Finally, studies have noted increased Testosterone (T) levels after acute injury. 
This study did not analyze T levels however increased T levels in response to critical illness may 
be implicated in both inflammation and ischemia.  In the study by Wagner et al., patients with 
severe TBI had lower Testosterone levels after injury which correlated with worse outcomes 
(Wagner et al., 2011).   
As described, the results from the current study demonstrate a r elationship between E1 
and E2 levels with both DCI and injury severity.  This relationship may be due to increases in E1 
and E2 levels that result from inflammation or other pathogenic mechanisms of injury severity, 
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thereby, representing an adaptive response for neuroprotection.  How E1 and E2 may be 
involved in the pathogenic response to injury are unknown and warrant further clinical 
investigation.     
 
3.6 CONCLUSION 
Our study provides preliminary evidence regarding the relationship between estrogen 
concentrations (E1 and E2) and injury severity as well as ischemic outcomes after aSAH.  These 
findings are however contrary to experimental studies which have repeatedly reported 
neuroprotective effects of estradiol and estrone after neurological insult and ischemia. Estrogen 
may be a protective response to injury which may lead to addition pathologic mechanisms that 
impact outcomes.  Certainly further work is necessary to better understand the role of estrogen in 
the brain and in the development of ischemic complications after aSAH in humans. 
 
3.7 LIMITATIONS 
This study only analyzed E1 and E2 levels after aSAH. Future studies including other 
neurosteroid levels (progesterone, allopreganalone and testosterone) as well as growth hormone 
(IGF-1) and inflammatory markers (cortisol, interleukins or CRP) could provide additional 
information and explanation for the findings. In addition, CSF was available for this sample. 
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Patients who require placement of external ventricular catheters represent a subgroup of aSAH 
patients who may have higher risk of complications after aSAH due to extent of injury including 
DCI.  A third limitation is the definition of DCI. In this analysis we defined DCI via components 
of altered blood flow in the presence of neurological deterioration. Although the definition is 
similar to the most recently defined criteria for DCI it does use TCD information in addition to 
cerebral blood flow and CT information.  Not all patients in this analysis had angiographic data 
available, as it is performed as a result of clinical changes rather than research protocols; 
therefore the correlation with angiographic vasospasm is on a subset of this patient sample. 
Furthermore determining a clinical change on a patient with poor neurological condition from 
the onset of injury limits the use of neurological assessment used to determine whether the 
patient has symptomatic ischemia.  
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Table 3. Demographics Plasma Estrogen Analysis N=99 
  FEMALE MALE 
 Pre-menopausal 
(N=28) 
Post-menopausal 
(N=34) 
 
N=37 
Age (Mean In Years) 43.54 (Sd=5.97) 59.1 (Sd=5.78) 47.5 (Sd=10.2) 
Race    
Caucasian 22 (79%) 31 (91%) 33 (89%) 
Other 6 (21%) 3 (9%) 4 (11%) 
Hunt and Hess    
1 2 (7%) 2 (6%) 1 (3%) 
2 9 (32%) 5 (15%) 11 (30%) 
3 12 (43%) 17 (50%) 16 (43%) 
4 4 (14%) 7 (21%) 9 (24%) 
5 1 (4%) 3 (9%) 0 (0%) 
Fisher    
2 14 (50%) 8 (24%) 14 (38%) 
3 10 (36%) 16 (47%) 19 (51%) 
4 4 (14%) 10 (29%) 4 (11%) 
DCI 16 (57%) 15 (44%) 14 (38%) 
DCI from vasospasm 14 (50%) 12 (35%) 12 (32%) 
DCI From CT 2 (7%) 3 (9%) 2 (5%) 
Vasospasm 12 (43%) 8 (24%) 10 (27%) 
Infarct 11 (39%) 10 (29%) 13 (35%) 
Ischemia 17 (61%) 18 (53%) 15 (41% 
Samples    
E1 Detection 84 (100%) 102 (100%) 110 (97%) 
E2 Detection 83 (99%) 96 (94%) 106 (95%) 
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Figure 3. Plasma E1 Trajectory 
Cnorm Model 2 group linear 
 Average probability per group 
             1            2 
 1        0.950        0.050 
 2        0.034        0.966 
Mixture Fit Statistics: Entropy 0.847; AIC 711.440; BIC 729.606; CAIC 736.606; ssBIC 707.499; CLC 718.390; 
ICL-BIC 750.556 
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Figure 4. Plasma E2 Trajectory 
Cnorm Model 2 group linear 
Average probability per group 
            1            2 
 1        0.911        0.089 
 2        0.073        0.927 
Mixture Fit Statistics- Entropy 0.729; AIC 721.700; BIC 739.866; CAIC 746.866; ssBIC 717.759; CLC 744.842; 
ICL-BIC 777.008  
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 Table 4. Trajectory analysis of (log) Plasma Estrogen measurements  
 E1 group E2 group 
 High 
n=61 
Low 
n=38 
pvalue High 
n=46 
Low 
n=53 
pvalue 
Gender   .02   .2 
male 17 20  14 23  
female 44 18  32 30  
Race   .25    
Caucasian  51 35  41 45 .61 
Other 10 3  5 8  
Age   <.001   .02 
Hunt and Hess   .31   .86 
HH 1  
HH 2  
HH 3  
HH 4  
HH 5  
2 3  2 3  
13 12  10 15  
29 16  21 24  
13 7  11 9  
4 0  2 2  
Hunt and Hess              1,2 23 15 .11 12 18 .33 
                                 vs 3-5 46 15  34 35  
Fisher    .008   .09 
2 24 12  17 19  
3 21 24  17 28  
4 16 2  12 6  
DCI                                no 14 24 .09 20 31 .13 
yes 31 27  24 21  
DCI-vasospasm sources no 34 23 .78 25 32 .5 
yes 24 15  20 19  
DCI-cerebral infarction  no 0 27 .03 28 35 .14 
yes 7 36  5 2  
Vasospasm                     no 24 6 .27 17 13 .79 
yes 20 10  16 14  
Ischemia                         no 32 17 .41 25 24 .39 
yes 29 21  21 29  
Infarct                             no 39 26 .74 29 36 .66 
yes 22 12  17 17  
Menopause   .05   .32 
pre-menopause 19 9  16 12  
post-menopause 25 9  16 18  
male 17 20  14 23  
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 Table 5. Univariate analysis of (log) Plasma Estrogen measurements adjusting for time 
 E1 E2 
 Mean Std dev pvalue Mean Std dev pvalue 
Gender   .06   .71 
male 4.2 .14  2.24 .14  
female 4.52 .1  2.31 .1  
Race   .66   .99 
Caucasian  4.38 .09  2.28 .09  
Other 4.48 .2  2.28 .24  
Age   <.001   .31 
Hunt and Hess   <.001   .02 
HH 1  
HH 2  
HH 3  
HH 4  
HH 5  
3.82 .34 .003 1.93 .32 .14 
4.15 .16 <.001 1.99 .19 .04 
4.39 .12 .004 2.35 .11 .55 
4.7 .17 .25 2.49 .18 .91 
4.95 .16  2.46 .16  
Hunt and Hess             1,2  4.09 .15 .014 1.99 .17 .02 
                                vs 3-5 4.51 .1  2.4 .1  
Fisher    .13   .19 
2 4.36 .14 .008 2.23 .16 .08 
3 4.22 .12 <.001 2.21 .12 .02 
4 4.86 .13  2.55 .11  
DCI                                no 4.18 .11 .004 2.11 .11 .03 
yes 4.64 .13  2.47 .13  
DCI-vasospasm sources no 4.32 .11 .33 2.2 .11 .16 
yes 4.49 .13  2.43 .14  
DCI-cerebral infarction  no 4.35 .11 <.001 2.27 .11 .05 
yes 5.16 .18  2.7 .2  
Vasospasm                     no 4.64 .13 .77 2.45 .14 .98 
yes 4.58 .15  2.44 .14  
Ischemia                         no 4.46 .11 .42 2.34 .13 .52 
yes 4.33 .12  2.23 .11  
Infarct                             no 4.36 .1 .52 2.27 .11 .8 
yes 4.47 .14  2.31 .13  
Menopause   .17   .33 
pre-menopause 4.45 .13  2.44 .14  
post-menopause 4.58 .14  2.18 .15  
male 4.2 .14  2.24 .14  
E1/E2      <.001 
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Appendix B 
PARENT STUDY POLICY AND PROCEDURE MANUAL 
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Appendix C 
PARENT STUDY CONSENT 
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Appendix D 
CSF TABLES AND FIGURES 
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D.1 CSF TABLE 6 
Table 6. Demographics CSF Estrogen Analysis N=36 
 Female Male 
 Pre-menopausal 
(N=11) 
Post-menopausal 
(N=11) 
 
N=14 
Age (Mean In Years) 43.36 (Sd=6.23) 60.91 (Sd=4.83) 46.4 (Sd=9.68) 
Race    
Caucasian 8 (73%) 10 (91%) 10 (71%) 
Other 3 (27%) 1 (9%) 4 (29%) 
Hunt And Hess              
1 2 (18%) 0 1 (7%) 
2 3 (27%) 1 (9%) 2 (14%) 
3 3 (27%) 5 (46%) 8 (57%) 
4 2 (18%) 3 (27%) 3 (21%) 
5 1 (9%) 2 (18%) 0 (0%) 
Fisher    
2 5 (45.5%) 1 (9%) 4 (29%) 
3 5 (45.5%) 4 (36%) 8 (57%) 
4 1 (9%) 6 (55%) 2 (14%) 
DCI 7 (64%) 5 (45.5%) 5 (36%) 
DCI from vasospasm 7 (64%) 3 (27%) 4 (29%) 
DCI From CT 0 1 (9%) 1 (7%) 
Vasospasm 7 (64%) 5 (45.5%) 4 (29%) 
Infarct 6 (54.5%) 4 (36%) 4 (29%) 
Ischemia 8 (73%) 5 (45.5%) 5 (36)% 
Samples    
E1 Detection 37 (76%) 47 (94%) 50 (81%) 
E2 Detection 16 (33%) 16 (50%) 21 (34%) 
 
 
 
 103 
 
D.2 CSF FIGURE 1 
 
111 222
 
Figure 5. CSF E1 2-Group Trajectory 
 
lgcsf E1 vs. day    cnorm model 2 group linear 
Average probability per group 
                   1            2 
  1        0.881        0.119 
  2        0.112        0.888 
Mixture fit statistics - entropy 0.637, AIC 359.780, BIC 370.865, CAIC 377.865, SSBIC  348.997, CLC 363.886, 
ICL-BIC  388.970 
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D.3 CSF FIGURE 2  
 
111 222 333
 
Figure 6. CSF E1 3-Group Trajectory 
 
lgcsf e1 vs. day 
cnorm model 3 group quad 
Average probability per group 
                 1            2            3 
  1        0.877        0.055        0.068 
  2        0.138        0.862        0.000 
  3        0.072        0.023        0.905 
Mixture fit statistics - Entropy  0.727,  AIC  355.220,  BIC  375.806,  CAIC 388.806,  SSBIC 335.194, CLC  
350.784, ICL-BIC  397.370 
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D.4 CSF FIGURE 3 
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Figure 7. CSF E2 Trajectory 
lgcsf E2 vs. day 
Cnorm Model 2 group linear 
Average probability per group 
                 1            2 
  1        0.877        0.123 
  2        0.223        0.777 
  Mixture Fit Statistics - Entropy   0. 425,  AIC  142.160,  BIC 153.245,  CAIC  160.245, ssBIC 131.377, CLC  
156.835, ICL-BIC  181.919 
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D.5 CSF TABLE 7: TRAJECTORY  ANALYSIS OF (LOG) CSF ESTROGEN MEASUREMENTS  
Table 7. Trajectory Analysis of (log) of CSF estrogen measurements 
 E1 E2 
 2 group 3 group 2 group 
 High 
n=14 
Low 
n=22 
pvalue High 
n=7 
Low 
n=24 
Decline 
n=5 
p 
value 
High 
n=26 
Low 
n=10 
p 
value 
Gender   .6    .009   .23 
male 6 8  3 6 5  12 2  
female 8 14  4 18 0  14 8  
Race   .28    .2   .5 
Caucasian  12 16  7 18 3  21 7  
Other 2 6  0 6 2  5 3  
Age   .11    .65   .46 
Hunt and Hess   .04    .69   .35 
HH 1  
HH 2  
HH 3  
HH 4  
HH 5  
0 3  0 2 1  1 2  
1 5  0 5 1  5 1  
5 11  3 11 2  13 3  
5 3  3 4 1  6 2  
3 0  1 2 0  1 2  
Hunt and Hess               1,2  1 8 .03 0 7 2 .2 6 3 .74 
                                  vs 3-5 13 14  7 17 3  20 7  
Fisher    .22    .46   .18 
2 2 8  0 8 2  6 4  
3 7 10  5 0 2  15 2  
4 5 4  2 6 1  5 4  
DCI                                 no 4 14 .12 3 12 3 .98 13 5 .93 
yes 9 8  3 12 2  12 5  
DCI-vasospasm sources no 3 16 .02 2 13 4 .37 15 4 .35 
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Trajectory Analysis of (log) of CSF estrogen measurements (continued) 
 E1 E2 
 2 group 3 group 2 group 
 High 
n=14 
Low 
n=22 
p 
value 
High 
n=7 
Low 
n=24 
Decline 
n=5 
p 
value 
High 
n=26 
Low 
n=10 
p 
value 
                                       yes 9 6  4 10 1  9 6  
DCI-cerebral infarction no 5 16 .42 3 15 3 .4 16 5 .45 
                                       yes 0 2  0 1 1  2 0  
Vasospasm                      no 4 6 .43 2 6 2 .47 8 2 .53 
                                       yes 10 6  5 10 1  11 5  
Ischemia                         no 6 12 .66 3 13 2 .7 14 4 .5 
                                       yes 8 10  4 11 3  12 6  
Infarct                             no 7 15 .47 4 16 2 .52 18 4 .15 
                                       yes 7 7  3 8 3  8 6  
Menopause   .83    .04    
                   pre-menopause 4 7  1 10 0  6 5  
                  post-menopause 4 7  3 8 0  8 3  
                                    male 6 8  3 6 5  12 2  
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D.9 CSF TABLE 8: UNIVARIATE ANALYSIS OF (LOG) CSF ESTROGEN MEASUREMENTS 
Table 8. Univariate analysis of (log) CSF estrogen measurements 
 E1 E2 
 Log measurements Detection Log measurements Detection 
 Mean Std 
dev 
p value Det 
n=33 
Ndet 
n=3 
p 
value 
Mean Std 
dev 
p 
value 
Det 
n=24 
Ndet 
n=12 
p 
value 
Gender   .67   .84   .44   .33 
male .96 .23  13 1  -.14 .28  8 6  
female 1.1 .18  20 2  -.38 .2  16 6  
Race   .09      .39   .78 
Caucasian  1.1 .16  25 3  -.26 .18  19 9  
Other .67 .26  8 0  -.58 .36  5 3  
Age   .08   .66   .79   .34 
Hunt and Hess   .03   .39   .92   .28 
HH 1  
HH 2  
HH 3  
HH 4  
HH 5  
.33 .38 .03 3 0  -.67 .61 .9 2 1  
  .74 .3 .01 6 0   -.09 .41 .45 4 2  
.97 .2 .2 13 3  -.25 .29 .33 8 8  
1.5 .24 .97 8 0  -.29 .29 .61 7 1  
1.5 .38  3 0  -.57 .49  3 0  
Hunt and Hess          1,2  .58 .24 .02 9 0 .3 -.27   .32 .87 6 3 1 
                             vs 3-5 1.2 .16  24 3  -.33 .2  18 9  
Fisher    .12   .16   .96   .69 
2 .66 .24 .06 10 0  -.39 .34 .93 6 4  
3 1.2 .21 .67 14 3  -.28 .23 .85 11 6  
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Univariate analysis of (log) CSF estrogen measurements (continued)
 E1 E2 
 Log measurements Detection Log measurements Detection 
 Mean Std 
dev 
p 
value 
Det 
n=33 
Ndet 
n=3 
p 
value 
Mean Std 
dev 
p 
value 
Det 
n=24 
Ndet 
n=12 
p 
value 
                                  yes 1.1 .2  16 1  -.19 .23  13 4  
DCI-vasospasm          no .7 .18 .05 17 2 .69 -.29 .27 .79 10 9 .1 
                                  yes 1.2 .2  14 1  -.38 .23  12 3  
DCI-cerebral infarct   no .74 .18 .84 19 2 .65 -.21 .23 .22 13 8 .74 
                                  yes .64 .44  2 0  .76 .74  1 1  
Vasospasm                 no 1.1 .27 .55 2 2 .29 -.1 .29 .55 8 2 .77 
                                  yes 1.3 .24  8 1  -.3 .23  12 4  
Ischemia                     no .99 .2 .77 17 1 .55 -.22 .24 .56 12 6 1 
                                  yes 1.1 .2  16 2  -.38 .22  12 6  
Infarct                        no 1.0 .18 .88 19 3 .15 -.27 .21 .68 14 8 .63 
                                  yes 1.1 .22  14 0  -.39 .25  10 4  
Menopause   .78  .3    .71    
               pre-menopause .97 .25 .98 9 2  -.43 .25 .42 9 2  
              post-menopause 1.2 .24 .52 11 0  -.3 .32 61 7 4  
                                male .96 .23  13 1  -.12 .29  8 6  
E1/E2   <.001          
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